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Acute myeloid leukaemia (AML) accounts for a quarter of all leukaemia and patients 
suffering from it have the lowest survival rates. For the past four decades, the standard 
chemotherapeutic treatment of AML is with anthracyclines and cytarabine, and cure rates 
have not improved drastically since. Unlike other cancers, there have not been any targeted 
treatments designed for AML that are currently in clinical use. This study focusses on the 
two commonly-occurring types of AML: AML with cytoplasmic mutant nucleophosmin 
(NPMc) and AML with wild type p53. Here, the mechanisms by which NPMc positive 
AML cells become resistant towards apoptosis and develop into leukaemia are investigated, 
and alternative means to treat the disease by targeting these mechanisms are proposed. In 
particular, the potential of inhibiting cytoprotective autophagy and preventing nuclear 
export as AML treatment are explored. Also, as more than 80% of AML are wild type for 
p53, this study delves into the role of Mdm4 in maintaining p53 in an inactive state and 
how Mdm4 downregulation is useful as a treatment for AML. In summary, this study 
uncovers new insights into the disease mechanisms of the two common occurrences of 
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1 Chapter 1 – Introduction 
1.1 Acute myeloid leukaemia 
1.1.1 Introduction 
Leukaemia accounts for approximately 2.2% of all cancers, with acute myeloid leukaemia 
(AML) accounting for about 25% of all leukaemia [1]. Though relatively rare, patients with 
AML have the lowest survival rates of all types of leukaemia, resulting in a 
disproportionately large effect on cancer survival statistics [2]. Although leukaemia is the 
most commonly diagnosed cancer in children, AML is predominantly a disease of late 
adulthood, with the median age of diagnosis of 66 years. Unfortunately, the survival rates 
of patients have not improved much over the past 30 years, with cure rates as low as 10% 
and with median survival less than a year for older AML patients [3-5]. Many patients 
younger than 60 years achieve complete remission, but the majority of them relapse, and 
less than half of these survive longer than five years [6, 7]. 
AML is a heterogeneous clonal disease characterised by the proliferation and accumulation 
of haematopoietic myeloid progenitor blast cells that fail to respond to signals to 
differentiate normally or to regulate cell division. These cells are unable to reach their 
intended fate as erythrocytes, thrombocytes, eosinophils, neutrophils, monocytes and 
macrophages, and accumulate largely in the bone marrow. This leads to organ infiltration 
and haematopoietic failure, which in turn greatly increases the risk of fatal infections and 
haemorrhages. Without treatment, death will ensue within one year of diagnosis, hence 
earning the ‘acute’ classification. Risk factors for acquiring AML include exposure to 
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ionising radiation, alkylating agents and cytotoxic drugs. In fact, up to 15% of patients 
develop AML after cytotoxic chemotherapy for other cancers [8]. 
1.1.2 Current practice of AML treatment 
The treatment of AML has largely been unchanged for the past four decades [9]. The 
worldwide standard, first-line treatment of AML consists of two phases of chemotherapy 
using a combination of anthracyclines, like daunorubicin or idarubicin, and cytarabine 
(AraC). The first phase, induction therapy, involves at least one course of intensive 
chemotherapy, and aims to achieve complete remission, which is defined as a marrow with 
less than 5% blasts, and a neutrophil and platelet count of more than 1000 and 100, 000 
respectively [10]. The second phase, consolidation therapy, aims to prolong complete 
remission by further reducing residual leukaemic blasts with increased doses of the drugs 
used in induction therapy [11]. Patients who have received consolidation therapy generally 
have better survivability of two to three years, compared to the disease-free survival of four 
to eight months in patients who have only undergone induction therapy [12]. Finally, 
disease-free patients can undergo maintenance therapy to further reduce residual leukaemic 
cells to prevent relapses [13], or if suitable, can undergo autologous or allogeneic stem cell 
transplantation [5]. 
Despite the long history of combined treatments with anthracyclines and cytarabine, 
current chemotherapeutics for AML still show unsatisfactory outcomes. Evidence indicates 
that simply increasing the dose of currently available cytotoxic drugs does not improve the 
clinical outcome [14, 15]. Because of this, there is low survival even with treatment, and a 
large number of patients, mostly those above 60 years old, exhibit poor tolerance to the 
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escalating doses of cytotoxic drugs [16]. Furthermore, anthracyclines and cytarabine 
exhibit cardiac [17] and neuronal [18] toxicity, in addition to the other types of toxicity 
associated with drugs targeting rapidly dividing cells. There is a dire need for new 
therapeutic strategies to combat these problems, spawning efforts to understand the disease 
pathology. The hope is that with better insight into the disease mechanism, new agents can 
be formulated to specifically target leukaemic cells, enabling lowered toxicity and better 
efficacy.  
1.1.3 Barriers at attaining targeted therapy of AML 
In spite of the promise of specifically-targeted anti-leukaemia therapies, the problem is that 
leukaemias, like all cancers, are not homogenous in their pathologies. Even though there 
are several types of AML that can be classified clinically, the underlying molecular 
mechanisms that bring about the disease are disparate. As advances in technology and 
research led to the emergence of new genetic and biologic data about cancers, the 
classification of these genetic diseases have moved beyond utilising cytochemical, 
immunophenotypic, morphological and clinical presentations to include genetic 
information as diagnostic markers. The outcome is the 2008 revision of the World Health 
Organisation (WHO) classification of tumours and haematopoietic and lymphoid tissues, 
part of the 4th edition of the WHO Classification of Tumors [19]. The new revision 
expanded the classification to include newly recognised diseases, as well as refined 
diagnostic criteria that utilise both scientific and clinical evidence [20]. More importantly, 
this revision acknowledges that the classification of AML based on genetic and molecular 
markers enables the study of the disease based on its underlying pathologies (Table 1.1). 
In doing so, this allows the development of therapeutics that target one type of disease 
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specifically over another, rather than the traditional generalised treatment that yields 
different outcomes in different patients.  
 
Table 1.1 Part of the 2008 WHO Classification of AML with recurrent genetic 
abnormalities, including newly recognised entities. 
AML with recurrent genetic abnormalities Occurrence 
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 10-15% [21] 
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 5-12% [22, 23] 
Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA 5-13% [24] 
AML with t(9 ;11)(p22;q23); MLLT3-MLL 2% (adult) [25]  
9-12% 
(paediatric) [26] 
AML with t(6;9)(p23;q34); DEK-NUP214 (new) 1% [27] 
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 (new) 1-3% [27] 
AML with mutated nucleophosmin (new, provisional) 30% [28] 
AML with mutated CEBPA (new, provisional) 10% [27] 
 
A new entry in the classification is AML with mutated nucleophosmin. This form of AML 
has been identified less than a decade ago and found to account for almost a third of all 
AML, making it the most common form of AML [28]. Missing in the 2008 classification, 
however, is information on the p53 status of the various forms of AML. Though mutations 
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in the tumour suppressor are present in more than half of all human cancers, p53 mutations 
in AML are relatively rare, accounting for only 10-15% of all AML [29].  
In this study, we are interested in exploring new ways for treating AML, especially through 
the exploitation of the mechanisms by which AML cells evade cell death. While it is 
unlikely that a single magic bullet exists to be used in the efficacious treatment of all AML 
types, it is possible to address the more commonly-occurring forms of AML. Specifically, 
this study will be investigate how the commonly observed AML cells with mutated 
nucleophosmin escape cell death, allowing leukaemogenesis. Also, we will look at the 
ways AML cells inactivate wild type p53, preventing the tumour suppressor from initiating 
cell cycle inhibition and cell death. By understanding the mechanisms behind preventing 
cell death, therapeutics could then be designed to specifically target pathways that these 
AML cells rely upon for survival and proliferation. 
1.2 The structure and function of nucleophosmin 
1.2.1 Structure of nucleophosmin 
The protein nucleophosmin 1 (NPM1, B23, numatrin, NO38) is encoded by the NPM1 
gene that resides on chromosome 5q35. The gene contains 12 exons, and at least three 
NPM1 transcripts have been identified: the longest and predominant isoform 1; the shorter 
isoform 2, which lacks an internal segment due to alternate in-frame splicing; and the 
isoform 3 that uses an alternative terminal exon to give it a different C-terminus. Of the 
three isoforms, isoform 1 is ubiquitously expressed and well characterised. On the other 
hand, the role and distribution of isoform 2 is unclear, while the function of isoform 3 
remains a complete mystery [30, 31].  
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Nucleophosmin 1 (NPM1), together with NPM2 and NPM3, belongs to the nucleoplasmin 
family, whose members share a conserved N-terminal core structure crucial for 
oligomerisation, the nucleoplasmin domain (Figure 1.1). This study only focuses on 
isoform 1 of nucleophosmin 1, henceforth simply referred as nucleophosmin (NPM). In 
NPM, this nucleoplasmin domain forms the N-terminal half of the protein and is rich in 
non-polar (1-110) and acidic (111-189) amino acids [32, 33]. The nucleoplasmin domain 
is not only responsible for NPM oligomerisation, but also required for many of its 
molecular chaperone activities, as well as efficient nucleolar accumulation [34]. Of note, 
the acidic central region of the protein is crucial for binding to histones H2A, H2B, H3 and 
H4. As such, NPM acts as a histone chaperone, allowing the formation and disassembly of 
chromatin templates in vitro [35]. Unlike NPM2 and NPM3, NPM has a unique C-terminal 
region that is rich in clusters of basic residues, involved in nucleic acid binding [36] and 
reported ribonuclease activities [32], and terminates with an aromatic stretch, important in 
nucleolar localisation [37].  
1.2.2 Localisation of NPM 
NPM is predominantly localised to the nucleoli, though it can translocate to the 
nucleoplasm and the cytoplasm. The ability of the protein to shuttle between the various 
compartments depends on the localisation motifs interspersed along its length. There are 
two nuclear export signal (NES) at amino acids 42-61 [38] and amino acids 94-102 [39].  
These two leucine-rich motifs are targeted by the nuclear export receptor protein Crm1 
(exportin-1) for translocation to the cytoplasm. The first NES (42-61) has been implicated 
in the nuclear export of the ribosomal protein L5, a 5S rRNA chaperone, making 
nucleophosmin a transporter of pre-ribosomal subunits. On the other hand, the second NES 
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(94-102) is required for nuclear export and centrosome localisation of nucleophosmin, 
important in ensuring proper centrosome duplication. A nuclear localisation (NLS) signal, 
at position 141-157 [39], is flanked by two acidic regions, and is responsible for the nuclear 
import of nucleophosmin. In addition, a nucleolar localisation signal (NuLS) is present at 
the region 243-294, of which the tryptophans W288 and W290 are crucial by stabilising 
the necessary structure for DNA binding [37]. The NES, NLS and NuLS (Figure 1.1) 
together form the basis of nucleolar-nuclear-cytoplasmic shuttling of NPM. 
 
Figure 1.1 Schematic representation of the regions and motifs of wild type 
nucleophosmin (wtNPM) and mutant cytoplasmic nucleophosmin (NPMc), showing 
the nuclear export signals (NES), nuclear localisation signal (NLS) and the two key 
typtophan residues (W288 and W290) that make up the nucleolar localisation signal 










































1.2.3 NPM in the control of transcription and ribosome synthesis 
NPM interacts with DNA, RNA and numerous proteins, making it a multi-functional 
protein. The C-terminus of NPM was identified to be essential in nucleic acid binding [36], 
and the role of this DNA binding ability is demonstrated by its function as a co-factor for 
the transcriptional activation of the mitochondrial superoxide dismutase 2 gene (sod2), 
where NPM binds to the G-rich region of the sod2 promoter [40]. Since then, the DNA 
binding capacity of NPM has been studied in greater detail, and it can potentially bind G-
rich DNA regions that contain G-quadruplexes [41].  
The abundance of NPM in the nucleolus, the centre of pre-ribosomal RNA synthesis, 
processing and packaging, aroused the suspicion that NPM could be involved in the 
formation of pre-ribosomal components. Indeed, studies have shown that NPM associates 
biochemically with ribonuclear proteins [42] and processes pre-RNA with its intrinsic 
ribonuclease activity [43, 44]. Interestingly, oligomerisation of NPM is crucial for RNA 
association [45]. Also, as mentioned previously, NPM was found to play a direct role in 
the nuclear export of ribosomal protein L5 for ribosome biogenesis [38]. In fact, 
knockdown of NPM by siRNA resulted in deficient processing of pre-rRNA to mature 28S 
rRNA [46]. Blocking the nuclear-cytosolic transport of NPM also resulted in reduced 
growth rates by directly inhibiting ribosome transport [47].Taken together, the evidence 
clearly indicates that NPM plays an important role in ribosomal biogenesis.  
1.2.4 Role of NPM in regulating genomic stability 
NPM is also necessary to maintain genomic integrity, as demonstrated by deficient 
centrosomal duplication in NPM +/- mice, which led to haematological abnormalities [48]. 
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In a resting cell, NPM associates with unduplicated centrosomes. However, during the late 
G1 phase, CDK2/cyclin E-mediated phosphorylation of NPM results in its disassociation 
from the centrosomes, allowing them to divide [49]. NPM then returns to the nucleolus 
until mitosis, where the breakdown of the nuclear envelope allows it to once again bind to 
the centrosomes to prevent a second duplication [50]. Furthermore, NPM is implicated to 
play roles in DNA repair, by which the protein is mobilised from the nucleolus to the 
nucleoplasm, where it binds chromatin in a DNA-damage dependent manner [51].  
1.2.5 Regulation of cell cycle progression and cell survival by NPM 
As a molecular chaperone, NPM affects the half-life, stability and accumulation of many 
of its binding partners. These proteins include the tumour suppressor ARF (p19ARF in 
mouse, p14ARF in human) [52, 53], F-box and WD repeat domain containing 7 (Fbw7γ) 
[54] and the ubiquitin-like protein/sentrin-specific peptidases 3 and 5 (SENP3, SENP5) 
[55], and the cell cycle inhibitor p21WAF1/CIP1 (p21) [56]. In addition, as a nucleo-
cytoplasmic shuttling protein, NPM is responsible for the transport of proteins in and out 
of the nucleus. Other than the nuclear export of the afore-mentioned ribosomal protein L5, 
NPM is also found to be important in the nuclear import of proteins without the classical 
NLS motif, such as HIV-1 Rev protein [57] and cell cycle regulator growth arrest and 
DNA-damage-inducible α-protein (Gadd45α) [58], and possibly acting as an accessory 
protein for import of other proteins containing a NLS, like taspase-1 [59]. 
The role of NPM in the control of cell cycle progression and cell survival is probably the 
most widely studied aspect of NPM, given the numerous implications of the protein in 
human disease. NPM is generally found to promote cell growth and survival, though the 
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mechanisms of action appear to be both cell type- and stimulus-specific. In haematopoietic 
cells, the over-expression of NPM has been found to reduce apoptosis and differentiation 
[60, 61]. Conversely, the differentiation of haematopoietic cells requires the down-
regulation of NPM [62]. In neuronal cells, NPM exerts an anti-apoptotic effect by 
inhibiting the fragmentation of DNA by caspase-activated DNase [63]. In Fanconi 
anaemia-derived lymphoblasts, NPM binds to and suppresses the pro-apoptotic activity of 
the protein kinase PKR [64]. NPM may also protect against apoptosis by retaining p53 
within the nucleus, thus preventing the pro-apoptotic mitochondrial accumulation of p53 
[65]. 
The overexpression of NPM has also been shown to enhance cell survival in response to 
various stress stimuli, including UV irradiation [66], ionising radiation [67], oncogene 
over-expression [68] and hypoxia [69]. Summarised in a review by Colombo et al. [31], 
the over-expression of NPM is associated either with increased DNA repair capability, or 
reduced levels of DNA damage, and has been correlated with reduced levels of S15-
phosphorylated p53, a modification linked to the p53-dependent apoptotic response [70]. 
Whether this correlation is as a result of NPM preventing p53 phosphorylation or a result 
of a reduced need for DNA damage response (by preventing DNA damage or enhancing 
repair) remains to be elucidated. The ability of NPM to attenuate p53-dependent apoptotic 
responses points to the possibility of the protein being proto-oncogenic. 
However, there is evidence to suggest that NPM can instead stabilise p53 and promote its 
transcriptional activity through direct interaction, leading to p53-dependent senescence [71, 
72]. Alternatively, NPM can also bind to Mdm2 (murine double minute 2, also called 
Hdm2 in humans). As Mdm2 acts as an E3 ubiquitin ligase on p53, the inhibition of Mdm2 
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by NPM prevents the targeted proteasomal degradation of p53, leading to its stabilisation 
[73].  
Another important NPM interacting protein is the tumour suppressor ARF. NPM is crucial 
in the prevention of ARF proteasomal degradation and its nucleolar localisation [74]. ARF 
triggers oncogene-induced cell cycle arrest by either inhibiting Mdm2-mediated p53 
degradation or through p53-independent pathways, such as interacting with and 
inactivating transcription factors, and reducing ribosome biogenesis [75, 76]. The 
importance of NPM in maintaining ARF levels is shown when NPM is overexpressed and 
the degradation of ARF is greatly diminished [52]. The same study also found that shRNA 
knockdown of NPM concordantly resulted in the rapid destruction of ARF and little or no 
ARF activity was observed.  
1.3 Nucleophosmin in disease 
Given the myriad of roles NPM performs, it would not be surprising to find that NPM is 
involved in a multitude of human diseases. Since many of the functions of NPM are closely 
related to tumour development, there are many studies that implicate NPM in cancer 
pathogenesis. Unfortunately, these studies have differing conclusions on whether NPM 
acts as a tumour suppressor or behaves like a proto-oncoprotein, though how NPM 
functions seem to be cell type dependent. 
1.3.1 Diseases with up- or down-regulation of NPM 
NPM has been found overexpressed in several carcinomas, including gastric [77], ovarian 
[78], prostate [79], colon [80] and bladder [81]. The overexpression of NPM has been 
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linked to increased ribosomal biogenesis and protein synthesis, both of which are 
heightened in cancer cells [82]. Also, NPM was found to cooperate with oncogenes to 
induce cellular transformation [68]. Furthermore, the overexpression of NPM reduced 
DNA damage imposed by the oncogenes, hampering oncogene-induced apoptosis and 
senescence. However, there is insufficient evidence to suggest that the overexpression of 
NPM is enough to lead to the oncogenic development of these tumours, or if the 
upregulation of NPM is due to increased oncogenic activity, especially since NPM1 is a c-
Myc target gene [83]. 
On the other hand, reduced levels of NPM in mice with NPM+/- background have been 
found to increase the rate of lymphoma onset [48]. These mice also have a greater incidence 
of developing haematological malignancies compared to the NPM+/+ mice, suggesting the 
importance of NPM in haematopoiesis [84]. MEFs derived from NPM+/- mice developed 
genomic instability and increased proliferation in later passages, and were more readily 
transformed by oncogene-expressing viruses. Combining the two seemingly conflicting 
observations yields a possible explanation on the role of NPM in tumourigenesis: 
overexpression of NPM could increase the DNA repair induced by oncogene activation 
and allow escape from the DNA-damage response, or reducing NPM levels can help to 
create genomic instability that favours further transformation events.  
1.3.2 Translocation of NPM genes 
In addition to differential expression, mutations involving the translocation of the NPM1 
gene are frequent in a number of leukaemias. These translocations yield oncogenic fusion 
proteins, such as NPM fusion to anaplastic lymphoma kinase (ALK). The fusion results in 
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a greatly increased expression of the mutant NPM-ALK and the constitutive activation of 
the kinase domain of ALK, triggering several downstream signalling pathways [85]. Other 
fusion proteins include NPM-RARα [86] and NPM-MFL1 [87], where the proper cellular 
localisation and, hence activity, is altered.  
1.3.3 Cytoplasmic mutant NPM in AML 
In recent years, a new type of NPM mutation has been identified in certain forms of acute 
myeloid leukaemia (AML). These AML are significantly characterised by having normal 
karyotypes in 85% of the cases, as opposed to leukaemias with chromosomal abnormalities, 
and are found in about a third of all adult AML cases. The heterozygous mutation happens 
almost exclusively at exon 12, and affects the C-terminus of the protein [28]. The result of 
these mutations is the loss of nucleolar signalling and the formation of a new C-terminus 
that matches an NES consensus sequence (Figure 1). As such, the mutant protein, instead 
of being predominantly localised in the nucleolus and nucleus, becomes exported and 
accumulated in the cytoplasm. Interestingly, this cytoplasmic mutant nucleophosmin 
(NPMc) is found only in AML. Furthermore, NPMc is stable in AML cells and could 
represent a mutation existing in the founder cells [88]. The NPMc mutant can be thought 
of as a dominant negative mutation, since the mutant protein can still oligomerise with wild 
type nucleophosmin (wtNPM) and result in its nuclear export [89].  
Since the discovery of NPMc, there are numerous studies initiated to uncover how the 
mutation can lead to disease formation. These studies focus on the functions of wtNPM 
and how the mutation would affect these functions. In particular, the localisation of NPM 
-interacting proteins was put under scrutiny and indeed, these proteins, including Miz1, 
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ARF and Fbw7γ, are aberrantly localised to the cytoplasm along with NPMc. Miz1 is a 
transcription factor controlling the expression of the cell cycle inhibitors p21 and p15INK4b, 
and NPMc delocalises Miz1 from the nucleus, preventing the expression of the two 
proteins and their control over cell cycle progression [90]. Similarly, ARF becomes 
displaced to the cytoplasm, where it would no longer inhibit Mdm2 and thus lead to p53 
degradation, as well as other p53-independent tumour suppressive activities [91]. Likewise, 
Fbw7γ, an E3 ubiquitin ligase responsible for the proteasomal degradation of c-Myc, is 
brought to the cytoplasm and degraded, allowing c-Myc stabilisation [92]. In combination, 
the effects of c-Myc stabilisation and removal of cell cycle inhibitors result in the 
unrestricted proliferation of NPMc+ cells. However, it appears that not all the functions of 
NPM are affected. For instance, ribosome biogenesis and centrosome duplication do not 
appear to be impaired, especially evident in the normal karyotypes of the vast majority of 
the cells harbouring the mutation.  
Unlike other types of tumours, p53 in AML remains largely unmutated [93]. In view of 
this, it has been proposed that p53 in leukaemia is kept inactive through Mdm2-mediated 
degradation. This is backed by evidence from studies involving the use of nutlin, a small 
molecule Mdm2 inhibitor [94]. Prevention of Mdm2-p53 interaction activates both the 
transcription dependent and independent apoptotic activities of p53, shown by increased 
levels of transcription of p53 targets like Noxa, as well as mitochondrial translocation of 
p53 and sequestration of anti-apoptotic Bcl-xL. This supports the notion that in NPMc+ 
AML cells, p53 is kept inactive by the lack of ARF-Mdm2 interaction. However, despite 
the ability of NPMc in preventing p53 activity, it is not sufficient to result in 
15 
 
leukaemogenesis, as shown by the need of the adenoviral oncoprotein E1A for NPMc-
expressing cells to escape senescence [95]. 
There exists the possibility that instead of losing the ability to perform the functions of 
wtNPM within the nucleus, the role of NPM in the cytoplasm could be enhanced by the 
NPMc mutation. NPM has been observed to translocate from the nucleolus to the 
nucleoplasm and the cytoplasm in response to cellular stress [96, 97]. Kerr et al. [96] 
reported that the cytoplasmic translocation of NPM activates and translocates Bax to the 
mitochondria to initiate an apoptotic response, and RNAi of NPM was able to attenuate 
apoptosis. On the contrary, another study conducted in our laboratory implicated NPMc in 
the inhibition of caspase-6 and caspase-8 signalling and prevented cell death in AML cells 
[98]. In addition, our study also found that the inhibition of the two caspases was linked to 
impairment in myeloid differentiation. These findings show that despite focus on how 
NPMc causes the loss of wild type NPM function, the role and gain-of-functions of NPMc 
in the cytoplasm cannot be ignored. 
Despite the possible roles of NPMc on oncogenesis, there is still the lack of a unified 
mechanism of how NPMc acts in vivo. Furthermore, many studies on NPMc are performed 
in non-haematopoietic cells like NIH-4T3 or MEFs, rather than the haematopoietic cells 
the NPMc mutation is exclusively linked to. This is compounded by the differing 
observations of the levels of expression of NPMc with respect to the wild type NPM, which 
in turn affects the tug-of-war that decides whether the NPM in the cell is predominantly 
cytoplasmic, nuclear or both [99]. Regardless of the disparate viewpoints, the strategy to 
achieve targeted therapy of NPMc positive AML remains the same: to selectively disrupt 
the mechanisms by which the leukaemic cells gain resistance towards cell death.  
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1.4 Wild type p53 in AML 
1.4.1 The tumour suppressor p53 
In the 1970s much of the attention in cancer science focused on tumour-causing viruses. A 
lot of effort was made in identifying viral and cellular oncogenes that were the cause of 
tumour transformation, and a popular tool in studying these oncogenes was the use of 
antibodies raised against viral tumour antigens. In 1979, a cellular protein of an apparent 
mass of 53kDa was co-immunoprecipitated using antisera against the SV40 large T antigen 
[100], which was previously demonstrated to be responsible for the tumourigenic 
properties of the SV40 virus. The same year, several other groups, using similar techniques, 
independently and simultaneously made similar discoveries [101-104], and later in 1983, 
the cellular protein was termed ‘p53’.  
Initially, p53 was thought to be an oncogene, owing to the observations that its cellular 
accumulation was driven by viral tumour antigens [105, 106], and that it was found to be 
in excessive quantities in tumour cells, but not in normal cells [107]. Because of this 
assumption, the p53 gene was cloned from tumour cells where the p53 protein was in 
abundance, and experiments utilising these clones further substantiated the idea that p53 
acted as an oncogene. However, when it was noted that inactivation and loss of p53 
promoted cancer formation [108, 109], and more importantly, when it was revealed that 
many p53 cDNA clones previously used to induce transformation carried mutations [110, 
111], it became clear that p53 may turn out not to be an oncogene after all. In fact, it was 
discovered that wild type p53 alleles in colorectal carcinomas were lost by mutation and/or 
deletion [112] and the expression of wild type p53 suppressed tumour formation [113]. 
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Subsequently, it was found that mutations in p53 were responsible for familial Li-Fraumeni 
syndrome, which resulted in early onset, cancer-prone phenotypes that were hereditable 
[114]. Furthermore, p53 knockout mice were extremely susceptible to spontaneously 
forming multiple types of cancers, even in the absence of mutated p53 [115]. This 
accumulating evidence unequivocally established p53 as a tumour suppressor, abdicating 
its status as an oncogene. Since then, more than half of all human cancers are found to have 
mutations in p53, and a large proportion of the remainder have impaired p53 pathways. It 
is one of the most widely studied proteins, with more than 60 000 publications listed in 
Pubmed, and the number is constantly growing. Despite the vast pool of knowledge we 
have on this tumour suppressor, there are still plenty of secrets yet to be uncovered. 
1.4.2 Structure of p53 
In spite of its very misleading moniker, the actual calculated molecular weight of human 
p53 is 43.7kDa. This discrepancy arose from the estimation of its molecular weight based 
on its electrophoretic mobility in an SDS polyacrylamide gel, which is retarded due to the 
presence of a proline-rich region that impairs movement within the gel matrices. The 393 
amino acid long protein is encoded by a 20kb gene located on the small arm of chromosome 
17 [116, 117], and consists of three functional domains: the N-terminal transcription 
activation domain, the central DNA binding domain, and the C-terminal oligomerisation 




The N-terminal transcription activation domains contain residues important in the 
interaction with basal transcriptional machinery and various transcription factors like 
acetyl transferases and methyltransferases [118-120]. This region can be divided into two 
smaller domains, the activation domain I and II (AD1 and AD2 respectively). The NMR 
structure of the activation region revealed that it is natively unstructured and unfolded, 
accounting for its ability to undergo folding upon interaction with other proteins, allowing 
p53 to bind to a variety of proteins of functional diversity [121, 122]. Deletion and mutation 
of the AD1 has shown that AD1 is responsible for inducing cell cycle arrest [123, 124], 
while similar experiments concluded that AD2 is primarily essential for p53-dependent 
apoptosis [125, 126].  
The central DNA binding domain (DBD) is critical for the role of p53 as a transcription 
factor. The crystal structure of the p53 DBD shows that much of it forms an anti-parallel 
β-sandwich that supports two large loops, held together by a cysteine- and histidine-
coordinated zinc atom, and a loop-sheet-helix motif [127]. These structures are responsible 
for making sequence-specific contact with the DNA phosphate backbone, as well as the 
minor and major grooves of the DNA helix. While a p53 monomer only binds to a 
Figure 1.2 Schematic representation of the structure of human p53, containing 
the N-terminal transcription activation domains, the proline-rich domain, the 
central DNA binding domain, and the C-terminal oligomerisation and basic 
domains. Also featured are the two activation domains (AD1, AD2), the nuclear 
localisation signal (NLS) and the nuclear export signal (NES). 
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pentameric sequence of the p53 response element, the p53 tetramer recognises the full 
consensus sequence that consists of two decameric sequences RRRCWWGYYY (where R 
= purine, C = cytosine, W = adenine or thymidine, G = guanine, Y = pyrimidine). The 
majority of p53 mutations affect this region of p53, making it a mutational hotspot. 
Mutations can affect residues critical in p53-DNA interaction or residues that are vital in 
maintaining the scaffold for the appropriate orientation of other residues responsible for 
contacting DNA, highlighting the importance of p53-dependent transcriptional activities 
in tumour suppression [128]. The DBD also interacts with proteins that both positively, 
like 53BP1 [129], and negatively, like the SV40 large T antigen [130], regulate the 
transcriptional activity of p53.  
NMR and crystal structure analyses of p53 revealed that p53 exists as a dimer of dimers 
through binding at the oligomerisation domain [131, 132]. While monomeric p53 can bind 
DNA in a cooperative manner, the affinity of tetrameric p53 for DNA is increased between 
10 to 100 times [133]. Tetramerisation of p53 aids in organising the four DBDs and 
achieving the correct orientation before interfacing with DNA, as well as the proper 
bending and twisting of DNA, thereby attaining increased DNA-binding specificity and 
affinity [134]. The oligomerisation domain is also crucial for protein-protein interactions, 
both in direct interaction with the oligomerisation domain, such as Ca2+ dependent protein 
kinase C [135], or indirectly with proteins that only interact with tetrameric p53, like Mdm2 
[136].  
The basic domain spans the last 50 amino acids of the p53 protein, so called because of the 
abundance of lysine and arginine residues. Like the central DBD, the C-terminal basic 
domain also binds DNA, albeit with very different DNA binding properties. Evidence 
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suggests that the basic domain facilitates search and binding of p53 to target promoters by 
promoting linear diffusion along DNA [137, 138]. Furthermore, the residues in the basic 
domain can undergo extensive post-translational modifications, enabling modification by 
acetylation, methylation, neddylation, phosphorylation, sumoylation and ubiquitination to 
regulate the function, localisation and stability of the protein [139].  
p53 contains nuclear localisation and nuclear export signals (NLS and NES) that enable 
the protein to rapidly shuttle between the nucleus and the cytoplasm. Since p53 acts as a 
transcription factor, the localisation of the protein plays an important role in regulating its 
function. Indeed, the NES and NLS are subject to post-translational modifications that 
control the subcellular localisation of p53 [140-142].  
1.4.3 Physiological functions of p53  
The main role of p53 is to act as a tumour suppressor: to prevent inappropriate cell 
proliferation and to maintain genomic integrity. To do so, p53 is stabilised and activated in 
response to a variety of cellular stimuli, such as DNA damage, hypoxia, growth factor 
depletion, heat shock and oncogene activation [143]. Upstream mediators that receive these 
stimuli transmit the signal through their respective functional pathways to activate p53 
proteins through modifications or accumulation. Downstream pathways are induced to 
bring about events to respond to the stress stimuli, most commonly through sequence-
specific transcriptional upregulation by p53. Moreover, p53 can transcriptionally repress 
genes that perform antagonistic functions, such as the anti-apoptotic survivin [144]. These 
transcriptional regulations trigger molecular events resulting in cell cycle arrest, cellular 
senescence or apoptosis. In addition, other signalling pathways can be triggered to bring 
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about DNA repair, metabolic changes or cell-to-cell communication. In general, the 
purpose of p53 is to mediate cellular repair upon cytotoxic insults, or in cases of other types 
of cytotoxic stress, induce programmed cell death. The p53-mediated outcome also 
depends on the cell type, as well as other less well-known factors [145]. 
In certain contexts, p53 can induce arrest in the G1, G2 and S phases of the cell cycle [146], 
allowing DNA repair to take place before the cell can proceed to complete DNA replication 
or cell division. p53 upregulates the transcription of p21 (or more accurately, p21Waf1/Cip1), 
a universal cyclin-dependent kinase (CDK) inhibitor that results in G1 arrest [147]. In 
addition, p53 mediates the expression of Gadd45 and 14-3-3σ, the former of which inhibits 
cyclin-B/CDK1 complex formation [148], and the latter of which mediates cyclin-B/CDK1 
nuclear export to prevent activation of its nuclear targets [149]. Both Gadd45 and 14-3-3σ 
effectively induce G2 arrest in cells. 
While cell cycle arrest can be a reversible phenotype, with cells progressing onto the next 
phase in the cell cycle after DNA repair, irreversible cell cycle arrest can occur in response 
to oncogene or stress signals, resulting in cellular senescence. p53-dependent cellular 
senescence is still poorly understood, though several p53 target genes can potentially 
delineate the underlying molecular mechanism[150]. p21 was found to be overexpressed 
in senescent cells [151] and its overexpression can lead to cellular senescence [152]. 
Similarly, plasminogen activator inhibitor 1 (PAI-1) is transcriptionally regulated by p53 
[153] and is upregulated in aging fibroblasts [154]. Not only does the RNAi of PAI-1 allow 
exit from senescence, the overexpression of PAI-1 induces premature senescence in mouse 
and human fibroblast cells [155]. Likewise, the p53-regulated transcription factor DEC1 
also causes cellular senescence [156]. 
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In cases when cells face irrevocable damage, p53 can mediate the induction of apoptosis 
to remove them from causing harm to the organism. p53 induces the expression of a large 
repertoire of apoptosis-mediating gene products that mediate cell death via the intrinsic or 
extrinsic apoptotic pathway. p53 target genes that are involved in the intrinsic apoptotic 
pathway include Bax [157], Puma [158], Noxa [159] and Apaf-1 [160], while genes 
involved in the extrinsic pathway include Fas [161], PIDD [162], and DR5/Killer [163].  
The intrinsic pathway centres about the mitochondria, where a family of Bcl-2 proteins 
regulate one another to prevent or cause the disruption of the mitochondrial membrane 
potential and promote the release of cytochrome c [164]. Mitochondrial membrane 
permeabilisation is achieved by pro-apoptotic members like Bax and Bak, which 
oligomerise to form pores that insert into the mitochondria outer membrane [165]. This is 
inhibited by the anti-apoptotic Bcl-2 family members like the Bcl-2 protein itself and Bcl-
xL. Other pro-apoptotic members, the BH3-only proteins, so called because they only 
contain one of the four Bcl-2 homology (BH) domain, induce mitochondria outer 
membrane permeabilisation indirectly by binding and inhibiting the anti-apoptotic Bcl-2 
members, or activating the pro-apoptotic Bax or Bak [166]. Upon cytochrome c release, 
apoptosomes are formed, made up of a complex of cytochrome c, Apaf-1 and caspase-9. 
This then triggers the downstream caspase cascade, which in turn mediates the proteolysis 
of proteins critical to cell survival and brings about apoptosis [167]. 
On the other hand, the extrinsic pathway involves the activation of death receptors on the 
plasma membrane, triggered by death ligands to receptors like Fas and DR5 [161, 163]. 
The activation of death receptors then activates caspase-8, which subsequently trigger the 
downstream caspases. The extrinsic pathway may also intersect with the intrinsic pathway, 
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for instance, through caspase-8 cleaved Bid, which is a BH3-only protein of the Bcl-2 
family [168].  
There has been emerging data that suggest a transcription-independent role of p53, in the 
absence of transcription or translation [169]. Transactivation-deficient p53 was 
demonstrated to induce apoptosis in cells, suggesting that transcription of pro-apoptotic 
p53 target genes may not be absolutely required for triggering apoptosis [170]. p53 can 
bind to Bcl-2 or Bcl-xL to prevent the anti-apoptotic proteins from inhibiting Bax or BH3-
only pro-apoptotic proteins, or directly induce Bax and Bak oligomerisation and 
mitochondrial membrane insertion [171, 172]. Though p53 may induce apoptosis in a non-
transcriptional, cytoplasmic manner, these processes may ultimately require products of 
p53 target gene expression [173]. Regardless, it is clear that p53-mediated apoptosis is a 
potent mechanism for p53 to function as a tumour suppressor. 
1.4.4 Regulation of p53 
Given that the tumour suppressor p53 is at the nexus of a vast network of signalling 
pathways, it is imperative that the protein is tightly regulated, lest unwarranted cell cycle 
inhibition and cell death would occur in normal, healthy cells. In fact, under normal 
circumstances, the concentrations of wild type p53 are kept at a very low level in a mostly 
inactive state [174]. The primary means of regulating p53 is modulating the levels of the 
protein through changes in the p53/Mdm2 feedback loop. 
The default mechanism to maintain low levels of p53 is through the negative regulation of 
p53 by Mdm2 (murine double minute 2, or more accurately, Hdm2, human double minute 
2, the human homologue of Mdm2). Mdm2 is a RING domain E3 ubiquitin ligase that 
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targets p53, mediating the transfer of ubiquitin moieties to p53, driving ubiquitin-mediated 
proteasomal degradation [175]. Though there are several E3 ligases known to target p53, 
Mdm2 appears to be the most important in terms of regulating p53 levels [176]. Knockout 
of Mdm2 results in early embryonic lethality in mice, and this can be rescued by 
simultaneous knockout of p53, indicating that Mdm2 is essential in controlling p53 activity 
[177]. The ubiquitin ligase activity of Mdm2 is dependent on its C-terminal RING domain, 
and binding of Mdm2 alone is insufficient in p53 inhibition [178]. The ubiquitination of 
p53 by Mdm2 drives the nuclear export of p53, concurrently preventing p53 transcriptional 
activity and inducing rapid degradation by proteasomes. This mechanism is a rapid and 
efficient means to regulate p53 by driving its proteosomal degradation, thus giving p53 a 
half-life of 20 to 30 minutes [179]. The p53 degradation pathway is made into a negative 
feedback loop because the Mdm2 gene promoter contains p53 responsive elements, making 
Mdm2 itself a p53 target gene [180, 181]. The levels of Mdm2 are also kept low by 
mediating its own ubiquitination and proteasomal degradation [182]. 
Other than inhibiting p53 through ubiquitin-mediated degradation, Mdm2 can directly 
inhibit p53 transcriptional activity by binding to the p53 transcription activation domains 
[175, 183]. It has been postulated that the interaction between the N-termini of both p53 
and Mdm2 results in p53 transcriptional inhibition, while the interaction between the 
central regions of Mdm2 and p53 is important in ubiquitination and degradation [184]. 
Together, the two inhibitory mechanisms of Mdm2 maintain p53 at low concentrations, as 
increases in p53 would lead to increased expression of its negative regulator Mdm2. p53 
activity is achieved by disruption of this autoregulatory loop, either through modifications 
in p53 or Mdm2. 
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Mdm4 (or MdmX) is another p53-regulating protein that shares significant levels of 
homology with Mdm2, in particular at the p53-binding and RING domains [185]. Mdm4 
is equally important as Mdm2 in regulating p53 in a non-redundant manner, as 
demonstrated by embryonic lethality in Mdm4-knockout mice [186]. Genetic experiments 
suggest that Mdm4 can regulate p53 in both Mdm2-dependent and independent manners 
[187]. Like Mdm2, Mdm4 can directly interact with p53 to inhibit its transcriptional 
activity [185]. However, unlike Mdm2, Mdm4 is not p53-regulated and by itself does not 
harbour any ubiquitin ligase activity [188]. The RING domains of the two proteins mediate 
their heterodimerisation [189], and in doing so stimulate Mdm2-mediated ubiquitination 
of p53 [190]. The expression of Mdm4 has been reported to be dependent on mitogenic 
signalling, and the transcription factors c-Ets-1 and Elk-1 have been implicated in Mdm4 
expression [191].  
The non-redundancy of Mdm4 has led to the recognition of the importance of the 
Mdm2/Mdm4 heterodimer. Experiments using non-GST tagged Mdm2 (because GST 
itself dimerises [192]) has demonstrated that Mdm2 by itself is a weak E3 ligase, capable 
of only multiple monoubiquitination of p53 [193]. While p53 monoubiquitination 
promotes nuclear export and inhibits p53 transcriptional activity, 26S proteasome 
recognition and degradation require the polyubiquitination of p53 [194]. Although other 
E3 or E4 (which mediates ubiquitin-ubiquitin conjugation) ubiquitin ligases may promote 
p53 polyubiquitination [195], the Mdm2/Mdm4 heterodimer promotes rapid and efficient 
p53 degradation, accounting for the rapid half-life of p53. The Mdm2/Mdm4 complex also 
mediates Mdm4 polyubiquitination and degradation, forming another feedback loop that 
can be disrupted to bring about p53 activation [193, 196], adding an additional layer of 
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complexity for control. Contrastingly, high levels of Mdm4 can stabilise p53 and Mdm2 
[197, 198], presumably due to competition for ubiquitination [193]. Furthermore, in normal 
conditions, Mdm4 is relatively stable, but rapidly declines in response to stress in an 
Mdm2-dependent manner [199]. Therefore, it seems that the stoichiometry of Mdm2, 
Mdm4 and p53 is critical in maintaining and determining p53 activity. This is confirmed 
in mouse models where clear evidence of haploinsufficiency has been seen in all three of 
these genes in the tumour suppressor response [200, 201]. Since regulating p53 degradation 
plays a crucial role in determining p53 activity, it is unsurprising to find that aberrations in 





Table 1.2 Aberrations in Mdm2 and Mdm4 in human tumours. Adapted from Toledo and 
Wahl [176]. 
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Figure 1.3 Phosphorylation sites of Mdm2 and Mdm4 by cellular kinases. Adapted from 




The primary mechanism that brings about inhibition or activation of p53 is the regulation 
of Mdm2 and Mdm4. The two RING proteins are capable of undergoing extensive 
phosphorylation on multiple residues that modulate their characteristics in affecting p53 
activity (Figure 1.3). Genotoxic stress induces signalling cascades that involve damage 
activated kinases that phosphorylate Mdm2 and Mdm4 can disrupt 
homo/heterodimerisation, prevent p53 binding, promote Mdm2/Mdm4 ubiquitination, and 
inhibit Mdm2/Mdm4 deubiquitination. For instance, in response to DNA damage, ataxia 
telangiectasia mutated (ATM) can phosphorylate both Mdm2 and Mdm4 to inhibit Mdm2 
oligomerisation and p53 ubiquitination, nuclear export and degradation [203, 204], while 
promoting Mdm4 ubiquitination and degradation [205], leading to p53 accumulation and 
activation. Phosphorylation of Mdm2 and Mdm4 has also been postulated to block 
HAUSP-mediated deubiquitination of Mdm2 and Mdm4, effectively promoting their 
degradation and p53 accumulation [206]. Conversely, dephosphorylation of Mdm2 and 
Mdm4 by the p53 transcription target Wip1 can inhibit p53 activity and allow resumption 
of cell cycle after DNA damage repair [207, 208]. On the other hand, the phosphorylation 
of Mdm2 and Mdm4 can also promote stabilisation of the two proteins and inhibit p53 
accumulation and activity. An example is the phosphorylation of Mdm2 and Mdm4 by Akt 
in response to growth factor stimulation [209, 210].  
Other proteins can interact with Mdm2 and Mdm4 to inhibit their function. As outlined in 
the previous section, ARF can bind to Mdm2 and sequester it to the nucleolus [211], as 
well as inhibiting Mdm2 ubiquitin ligase activity [212]. This promotes p53 accumulation 




While the ubiquitination of p53 serves as an effective means to regulate its activity through 
its concentration, p53 activity can be modulated through a large number of other forms of 
post-translational modification, like phosphorylation, acetylation, methylation and 
sumoylation. Given its importance in cancer, post-translational modifications of p53 are 
extensively studied, and to date there are modifications of various types at about 50 sites 
throughout the polypeptide chain, and many of them are barely understood. The scale of 
the extent of modification is utterly mind-boggling and beyond the scope of this 
dissertation, but it can be categorised by the outcome of the modification, summarised in 




Figure 1.4 The major domains of p53 and the locations of post translational modifications 
sorted by outcomes. Only modifications directly implicated for the outcomes are included. 
Adapted from Gu and Zhu (2012) [212].  
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The effects of post-translational modifications changes the way a binding partner, another 
protein or DNA, can interact with p53. For instance, DNA damage-induced p53 
phosphorylation on S33, T91 and S315 creates a docking motif for Pin1, a peptidyl-prolyl 
isomerase, to bind and mediate cis-trans isomerisation of the prolines in the transactivation 
domains to promote transcription of target genes [215, 216]. The number and scale of post-
translational modifications further exemplifies the complexity of the p53 network, in its 
ability to receive signals from various upstream, stimuli-sensing pathways, to initiating 
several downstream effector pathways simultaneously. The mutation or loss of p53, or one 
or several of its binding partners, would elicit profound changes on the physiology in the 
cell. 
1.4.5 p53 in cancer and leukaemia 
The tumour suppressor p53 plays a critical role in maintaining genomic integrity and 
limiting aberrant proliferation, and p53 mutation is the most common genetic anomaly in 
human cancers [217]. Defects in the pathways that regulate p53 also accounts for a large 
majority of the cancers with wild type p53, stressing the importance of this central tumour 
suppressor in cancer pathogenesis.  
p53 mutations are distributed in all the coding exons of the gene, with high frequencies in 
the hotspot region in exons 4 to 9, which correspond to the DBD of the protein [127]. Most 
of the mutations that occur in this region are within the six hotspot residues R175, G245, 
R248, R249, R273 and R282, suggesting these residues are important in limiting cancer 




Many mutations of p53 exert their effects on wild type p53 in a dominant negative manner, 
owing to the fact that p53 tetramerisation is required for its transcriptional activity [218, 
219]. This heterozygous state is frequently followed by the loss of the remaining wild type 
p53 allele, implying that the loss of heterozygousity is a positively selected event in 
tumourigenesis. Furthermore, some p53 mutations are gain-of-function mutations, 
resulting in additional oncogenic activity over that of dominant negative mutations. These 
mutations provide new functions of the protein that contribute to tumour progression, 
metastasis and resistance to anti-tumour therapeutics [220]. 
Unlike solid tumours, p53 mutations are relatively rare in AML, accounting for only 10-
15% of all diagnosed cases. Nonetheless, AML with mutated p53 are associated with 
aggressive disease development and resistance to chemotherapy [221]. In cases of AML 
where p53 is wild type, mutations in the regulators of the p53 pathway are usually 
responsible for inactivating the tumour suppressive functions in p53. For instance, Mdm2 
overexpression was documented in about 50% of leukaemias [222], and Mdm4 
amplification was found in at least some instances of AML [223]. Alternatively, 
downstream effector pathways of p53 can be perturbed to prevent the tumour suppressive 
activities of p53, such as the high levels of anti-apoptotic Bcl-2 family members Bcl-XL 
and Mcl-1 [224, 225]. 
Due to the availability of functional, wild type p53 in a large proportion of AML, strategies 
involving the activation of p53 in these leukaemic cells have been proposed and several 
studies using the Mdm2 antagonist nutlin-3 have yielded promising results [226]. However, 
not all AML patients respond similarly to Mdm2 inhibition despite having unmutated p53 
[227]. Though correlations to mutations in Flt3 have been made, not much is understood 
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about the discrepancies in treatment outcome, and even less is known on how to treat this 
subset of AML other than classifying their prognoses.  
1.5 Objectives of study 
Cancer was once an incurable disease, but as our understanding of it grew, we have become 
more able to manage the disease, and in some cases, achieve and maintain long periods of 
remission, greatly improving the quality of patients’ lives. Studies on various forms of 
cancer have led to the deciphering of the disease mechanisms, and the development and 
use of new generation of targeted drugs, such as imatinib for chronic myelogenous 
leukaemia and trastuzumab for breast cancer.  
Despite accounting for a small proportion of all human cancers, AML unfortunately is 
responsible for a disproportionately large percentage of mortalities. There have not been 
significant developments in the field of AML therapeutics in the past four decades, other 
than optimising the dose of similar broad-acting chemotherapeutic agents. Unlike other 
forms of cancer, there is a sore need for new, targeted approaches to specifically act on the 
disease and lower the mortality rates of AML.  
With this in mind, this study aims to investigate the disease mechanisms of two of the most 
common types of AML: NPMc positive AML, which accounts for a third of all AML, and 
AML with wild type p53, which include at least 80% of all AML cases. In uncovering the 
pathways involved in contributing to cell death resistance, an important hallmark of cancer 
development and therapeutics, the objective of this study is also to propose potential 
strategies to treat AML in a specific and targeted approach.  
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2 Chapter 2 – Materials and methods 
2.1 Cell culture  
OCI/AML-2 (AML2, from DSMZ), OCI/AML-3 (AML3, from DSMZ) and MOLM13 
cells were cultured in Alpha MEM (Invitrogen) supplemented with 20% foetal bovine 
serum (FBS, from Hyclone) and 1% penicillin/streptomycin (100U/ml penicillin and 
100µg/ml streptomycin; Invitrogen). HL60 cells were obtained from ATCC and cultured 
in Iscove’s MEM (Sigma) supplemented with 20% FBS and 1% penicillin/streptomycin. 
HEK 293T cell (gift from Dr. Low Boon Chuan, NUS) and THP1 cells were cultured in 
RPMI 1640 (Sigma) supplemented with 10% FBS and 1% penicillin/streptomycin. Cell 
lines were maintained within a humidified atmosphere of 5% CO2 at 37oC and passaged at 
90% confluence.  
2.2 Plasmid constructs  
Total RNA from AML3 cells were isolated and reversed transcribed and amplified with 
PCR using gene specific primers with EcoRI cut sites targeting the NPM open reading 
frame (ORF): forward primer: 5’-GAA TTC TAT GGA AGA TTC GAT GGA CAT-3’; 
reverse primer: 5’-GAA TTC CTA TTT TCT TAA AGA GAC TTC CTC-3’. The PCR 
product was ligated to pGEM T vectors (Promega) and excised with EcoRI. The cut 
fragments were ligated with similarly cut pAcGFP1-C1 vector (Clontech) and after 
sequence verification, the subsequent pAcGFP1-C1-wtNPM and pAcGFP1-C1-NPMc 
plasmids were isolated. Lentiviral vectors carrying GFP, GFP-wtNPM and GFP-NPMc 
were obtained by cloning from the genes from pAcGFP-C1, pAcGFP1-C1-wtNPM and 
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pAcGFP1-C1-NPMc plasmids respectively into pLenti 6.3 V5 (Invitrogen) plasmid 
backbone. 
The pRFP-LC3 plasmid for expression of RFP-tagged LC3 was obtained from Dr. Noburu 
Mizushima (Tokyo Medical and Dental University, Tokyo, Japan). 
To obtain recombinant NPM, the wtNPM ORF was excised from the pAcGFP1-C1-
wtNPM plasmid using EcoRI and cloned into pET32b vector (Novagen), creating the gene 
fusion expressing a thioredoxin and polyhistidine-tagged NPM (His-NPM). Similarly, to 
obtain glutathione S-transferase (GST) tagged wtNPM or NPMc, the wtNPM or NPMc 
ORF were excised from the respective pAcGFP1-C1 vectors using EcoRI and cloned into 
the pGEX 4T-3 vector (GE Healthcare), producing a gene fusion that expressed N-terminal 
GST-tagged wtNPM or NPMc. All cloning of gene constructs were verified by gene 
sequencing. 
2.3 Cell transfection and transduction 
HEK293T cells were transfected with Lipofectamine 2000 (Invitrogen) using 
manufacturer’s recommendations. The leukaemic cells lines were transfected using the 
Amaxa Nucleofector Kit V with 2µg plasmid DNA per 1.0 x 106 cells, using the following 
programmes: AML2 and AML3: X-001; THP1: T-019; HL60: U-013. 
Lentiviruses were produced with Lipofectamine 2000 transfection of HEK293FT cells 
(Invitrogen) with pLenti 6.3 V5 plasmids with genes for GFP, GFP-wtNPM or GFP-NPMc. 
Packaging plasmids pLP1, pLP2 and pLP/VSVG were co-transfected with the 
corresponding pLenti 6.3 V5 plasmids to drive production of lentiviral particles. Virus-
36 
 
containing media was obtained after 24 and 48 hours post-transfection and cell debris was 
removed by centrifugation at 4000 rpm for 15 minutes at 4oC. The virus particles were 
concentrated by centrifuging the supernatants at 16 000 rpm for 1.5 hours at 4oC using a 
fixed angle JA-20 rotor (Beckman Coulter). The pellet was resuspended in Alpha MEM 
and used immediately for transduction. Transduction was performed by centrifuging 
AML2 cells with resuspended viruses at 900g for 1 hour at room temperature, and stable 
transductants were selected 24 hours post-transduction with 0.6µg/ml blasticidin (Sigma). 
Cells expressing the transgenes were sorted from the non-fluorescing and dead cells by 
fluorescence assisted cell sorting using a BD FACSAria II cell sorter. 
2.4 Recombinant protein expression and purification 
For recombinant protein expression and isolation, the pET32b-NPM plasmid was 
transformed into Escherichia coli BL21 (DE3) pLysS bacteria (Novagen). After growth in 
LB media to an optical density of 0.8 at 600nm, the bacteria were induced to express the 
recombinant proteins with 0.1µM isopropyl thiogalactopyranoside (Biorad) for 6hr at room 
temperature. Bacteria were collected by centrifugation, resuspended and lysed by 
sonication, with 10s pulses at 40% amplitude for 4 min with 10s intervals, in 10 ml lysis 
buffer (1x physiologically buffered saline (PBS), 1.5% dithiothreitol, 1% protease inhibitor 
cocktail mixture (Roche Molecular Biochemicals), 1% Triton X-100). The lysate was 
cleared by centrifugation and the His-tagged proteins were purified by affinity 
chromatography using Ni-NTA agarose (Qiagen) according to the manufacturer’s 
recommendations. Bead-bound proteins were washed with PBS with 1% Triton X-100 and 
10mM imidazole. Proteins were eluted with PBS containing 100mM imidazole and the 
eluted proteins were concentrated with Vivaspin centrifugal concentrators (Sartorius), 
37 
 
while exchanging their buffers for PBS. Concentrated proteins were quantified using 
Bradford assays (Biorad, USA). The His tag from His-NPM was cleaved by incubating 
with 3U thrombin (Sigma, USA) per mg protein at 37oC for 1 hr in buffer containing 
200mM NaCl and 50mM Tris-Cl at pH 7.9. The 37kDa recombinant NPM (rNPM) was 
purified using a Sephadex G-75 (Sigma, USA) gel filtration column. Thrombin was 
removed by incubating with p-aminobenzamidine agarose (Sigma, USA) at 4oC overnight 
with gentle rotation. Recombinant protein purity was assessed using SDS-PAGE, 
visualized with Coomassie Blue. 
GST-tagged wtNPM and NPMc were created similarly, with the exception that glutathione 
Sepharose beads (GE Healthcare) were used. Protein-bound beads were washed five times 
with PBS with 1% Triton X-100 before a final wash with PBS. The beads were normalised 
based on protein concentration quantified by a Bradford assay before use in GST-pulldown 
experiments. 
2.5 Cell death assays 
Apoptosis was assayed by visualisation of condensed nuclei of DAPI-stained cells. Briefly, 
THP1 or HL60 cells were cytospinned onto glass slides and fixed with 3.7% 
paraformaldehyde before staining with DAPI-containing mounting media (Vector 
Laboratories). Cells were observed and imaged under an Olympus BX60 compound 
fluorescence microscope and cells with condensed nuclei were enumerated. 
Apoptosis was also assayed by flow cytometry using Annexin V staining. Cells were 
washed with PBS before staining with 1µl Annexin V-Cy5 (Biovision) in 500µl Annexin 
V binding buffer (10mM HEPES pH 7.4, 140mM NaCl, 2.5mM CaCl2). Cells were 
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analysed with a BD LSR II (BD Biosciences) and data analysis was performed with 
Flowing Software (Turku Centre for Biotechnology). 
2.6 Confocal microscopy 
For microscopy, adherent cells were grown on glass coverslips while suspension cells were 
spread onto glass slides. The cells were fixed with 3.7% paraformaldehyde in PBS and 
permeabilised with 0.2% Triton X-100. For immunofluorescence, blocking was performed 
with 5% goat serum in PBS for 1 hour before overnight incubation with primary antibodies 
at 4oC. The cells were washed thrice with PBS before incubation with AlexaFluor-labelled 
secondary antibodies (Invitrogen, 1:1000) for 1 hour at room temperature. The primary 
antibodies used were mouse anti-p53 (DO-1, 1:500) or mouse anti-NPMc (1:200). The 
cells were imaged using a Zeiss LSM510 confocal microscope and images were processed 
with Zeiss ZEN software.  
For quantification of autophagy puncta, images were processed using ImageJ. The red 
fluorescence of the RFP-LC3 puncta was demarcated by lowering the background 
fluorescence to allow quantification by the ImageJ software. Puncta larger than 0.0225µm2 
per cell was quantified.  
2.7 Subcellular fractionation and cell lysis 
Nuclear and cytosolic fractions were prepared using a Nuclear/Cytosol Fractionation Kit 
(Biovision) according to manufacturer’s recommendations, except for an additional PBS 
wash of the isolated nuclei before lysis with SDS lysis buffer. For immunoprecipitation, 
cell lysates were prepared using detergent-free lysis buffer (20mM Hepes-KOH, pH 7.5, 
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10mM KCl, 1.5mM MgCl2, 1mM EDTA, 1mM EGTA, 3mM dithiothreitol, 1% protease 
inhibitor cocktail) and dounce homogenisation. For whole cell lysates and cell nuclei, cells 
were lysed in 95oC SDS lysis buffer (20mM Tris-Cl pH 8.0, 2% SDS, 10% glycerol), 
followed by a brief sonication to shear DNA. 
2.8 Protein electrophoresis and Western blotting 
Equal amounts of protein, as measured using a BCA protein quantification kit following 
manufacturer’s recommendations (Pierce, USA), were loaded in SDS-PAGE gels and 
transferred onto nitrocellulose membranes with the iBlot system (Invitrogen, USA). The 
primary antibodies used were: mouse anti-GFP (Santa Cruz; 1:5000), rabbit anti-LC3 (Cell 
Signaling; 1:1000), rabbit anti-Bcl-2 (Cell Signaling; 1:1000), mouse anti-Bax (BD 
Pharmingen; 1:2000), rabbit anti-PI3K III (Cell Signaling; 1:1000), rabbit anti-Beclin-1 
(Cell Signaling; 1:1000), rabbit anti-Oct1 (Santa Cruz; 1:1000), rabbit anti-NPM (Cell 
Signaling, 1:1000), mouse anti-NPMc (p53Lab, 1:1000), mouse anti-p53 (clone DO-1; 
1:5000), mouse anti-Mdm2 (clone 2A9; 1:5000), rabbit anti-Mdm4 (Bethyl Laboratories 
Inc., USA; 1:5000), mouse anti-p21 (clone 118; 1:2000), rabbit anti-USP2a (Abcam; 
1:1000), rabbit anti-USP5 (Abcam; 1:1000), mouse anti-p14 ARF (Abcam; 1:1000), mouse 
anti-β-actin (AC15; Sigma, USA; 1:10 000), and mouse anti-GAPDH (Ambion, USA; 1:10 
000). Secondary antibodies conjugated to HRP (Dako, USA; 1:10 000) were detected using 




2.9 Flow cytometry analysis of p53  
105 cells were fixed and permeabilised in ice cold 70% ethanol and incubated for 30 
minutes at -20oC. The cells were washed with PBS and stained with 1µg mouse anti-p53 
(DO-1) or mouse isotype control antibody, washed thrice with PBS and stained with 1µg 
goat anti-mouse Alexa488 (Invitrogen), and washed thrice. Finally, the cells were stained 
with PBS containing 10µg/ml propidium iodide and 5µg/ml RNase A. Flow cytometry 
analysis on single cells was performed with BD LSR II (BD Biosciences, USA). Data 
analysis was performed using Flowing Software (Turku Centre for Biotechnology).  
2.10 RNAi of Mdm4 
2 x 106 AML2 or AML3 cells in logarithmic growth were transfected with 1µM pool of 
siRNA against Mdm4 or non-targeting siRNA as a control (ONTARGETplus SMARTpool, 
from Thermo Scientific). Transfection was performed with Amaxa Nucleofector Kit V 
using programme X-001. The cells were allowed to rest for 24 hours in media before further 
treatment. Post-transfection cell viability, based on propidium iodide exclusion, was 
assayed using an ADAM automated cell counter (Digital Bio). 
2.11 Quantitative real time PCR 
Total RNA was extracted from AML2 and AML3 cells with a Qiagen RNAeasy Kit. cDNA 
was obtained by reverse transcription using random hexamers and 1µl (5% of the reaction) 
was used as the template for subsequent real time PCR with 1µM forward and reverse 
primers, and 2X iQ Supermix (Biorad). The reactions were performed in triplicate in a 384-
well format with 10µl reaction volume. The primer sequences used are listed in Table 2.1. 
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The melt curve for each primer set was verified to have a single distinct peak and gel 
electrophoresis of the PCR products only produced one clear band. 
Table 2.1 Primers used for quantitative real time PCR 
p53 
Forward 5’ – TCAACAAGATGTTTTGCCAACTG – 3’ 
Reverse 5’ – ATGTGCTGTGACTGCTTGTAGATG – 3’  
Mdm2 
Forward 5’ – GAGACCCTGGTTAGACCAAAGCC – 3’ 
Reverse 5’ – GATCCGGATTCGATGGCGTCC – 3’ 
p21 
Forward 5’ – ACTCAGAGGAGGCGCCATGT – 3’  
Reverse 5’ – CCAGGCGAAGTCACCCTCCA – 3’ 
Noxa 
Forward 5’ – GTGCCCTTGGAAACGGAAGA – 3’ 
Reverse 5’ – CCAGCCGCCCAGTCTAATCA – 3’ 
Mdm4 
Forward 5’ – GCAAGAAATTTAACTCTCCAAGCAA – 3’ 
Reverse 5’ – CTTTGAACAATCTGAATACCAATCCTT – 3’ 
GAPDH 
Forward 5’ – CGCATCTTCTTTTGCGTCGCC – 3’ 
Reverse 5’ – CTGCAAATGAGCCCCAGCCTT – 3’ 
 
2.12 Enzyme-linked immunosorbent assay (ELISA) 
20 µg/ml mouse anti-p53 (clone Bp53 10.1) were immobilised onto high binding capacity 
polystyrene 96-well plates (Corning) and incubated with  a cell extract prepared by cell 
lysis of 2 x 107 cells /ml in 50mM Tris-Cl pH 8.0, 150mM NaCl, 10mM EDTA, 0.1% NP-
40, 5mM NaF, 200µM Na3VO4, 1mM dithiothreitol, 1x protease inhibitor cocktail 
(Roche). After washing with PBS, protein complexes were detected with using HRP-
conjugated mouse anti-Mdm2 (clone 2A9), HRP-conjugated mouse anti-p53 (clone DO-
1), or rabbit anti-Mdm4 (Bethyl) followed by secondary HRP-conjugated anti-rabbit IgG 
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(Dako) and TMB substrate (Bio-Rad). Absorbance at 450nm was measured using an 
EnVision Plate Reader (Perkin Elmer).  
2.13 Proximity Ligation In Situ Assay (PLISA) 
PLISA was performed using the Duolink In Situ Kit (OLink Biosciences) according to 
manufacturer’s protocols. Cells smeared onto Polysine (Thermo Scientific) glass slides 
were fixed with 3.7% paraformaldehyde in PBS and permeabilised with 0.2% Triton X-
100 in PBS, blocked and incubated with 5 µg/ml of the following antibodies: mouse anti-
p53 (clone Bp53 10.1) and rabbit anti-Mdm4 (Bethyl), or mouse anti-Mdm2 (clone 2A9) 
and rabbit anti-p53 (clone CM-1). Images comprising 30 0.49µm-thick z-stacks were 




3 Chapter 3 – Cytoprotective autophagy in NPMc+ AML 
3.1 Introduction 
NPMc mutations in nucleophosmin (NPM) account for the largest subtype of acute 
myeloid leukaemia, distinguished from the other forms by the aberrant translocation of 
NPM from the nucleus to the cytoplasm. Despite its importance in characterising the 
subgroup, little is known about how the NPMc mutant perturbs molecular pathways to 
bring about the development of the disease. Although many groups seek to find 
explanations by investigating the changes brought about by the loss of function of NPM in 
the nucleus, not many studies focus on the abnormal relocalisation of NPMc. Wild type 
NPM shuttles in and out of the nucleus, but its presence in the cytoplasm is mainly transient. 
With this in mind, it would be of great interest to study the implications of the mutant NPM 
taking up permanent residency in the cytoplasm.  
An important hallmark of cancer is that cancer cells are particularly resistant to cell death. 
This confers a selective advantage, leading to the development of leukaemic cells, enabling 
the acquisition and accumulation of further mutations that would otherwise activate cellular 
oncogenic responses and result in apoptotic cell death. Therefore, in order to remove this 
advantage of cell death resistance, it would be valuable to investigate the molecular basis 
for this phenomenon.  
Macroautophagy, or more commonly termed as autophagy, is a well-established process 
by which cytoplasmic components are sequestered into vesicles and degraded by lysosomal 
degradation. This process serves as a catabolic process to degrade long-lived proteins and 
organelles, recycling their components for other uses. Although autophagy was first 
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described more than half a century ago, it is only in the last decade that, with the 
understanding of its molecular mechanisms, it has garnered more interest, particularly 
focusing on its role in disease processes.  
The role of autophagy in carcinogenesis was implied by the discovery that Beclin1, a key 
component of the class III phosphoinositide 3-kinase (PI3K III) complex responsible for 
the formation of autophagy vesicles, may function as a tumour suppressor. This came about 
from the observations that beclin1 mutations occurred in a large proportion of several 
cancer types, including prostate, breast and ovarian cancers [228], and that beclin1 
overexpression led to autophagy induction and inhibition of tumourigenesis [229]. Since 
then, several other genes involved in the regulation of autophagy have been implicated in 
tumour suppression, including atg5, atg4c, uvrag, and ambra1 [230-232]. Despite our 
understanding of the players involved, there are no definite mechanisms that directly link 
autophagy to tumour suppression, although several models have been proposed and 
investigated. These models include the removal of aged and damaged organelles to reduce 
oxidative stress, participation in cell death pathways not unlike apoptosis (“autophagic cell 
death”), and the inhibition of connected apoptosis signalling pathways [233]. 
Evidence from recent studies, however, paint autophagy in a different light. Inhibition of 
autophagy by preventing autophagosome-lysosome fusion triggered apoptotic programmes 
[234] or sensitised cells to cytotoxic insults [235]. On the other hand, induction of 
autophagy by rapamycin treatment or Beclin1 overexpression protected cells against 
apoptosis [235]. Autophagy was also found to protect carcinoma cells from radiotherapy-
induced apoptosis, as well as confer resistance towards chemotherapeutic drugs [236-239]. 
As such, there is now clear evidence to suggest that autophagy acts as a cytoprotective 
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mechanism to protect cells from various forms of cytotoxic stress, and is highly implicated 
in contributing to chemoresistance in various cancers. 
Here, we sought to determine the mechanisms by which NPMc, a common mutation in a 
large proportion of AML, can bring about leukaemogenesis.  Understanding the basis by 
which this subset of AML develops can help to develop new therapeutic strategies to offer 
targeted treatment to these cancer patients.  
3.2 Results 
3.2.1 NPMc expression confers resistance towards cell death 
In this study, the acute myeloid leukaemia cell lines OCI/AML-2 and OCI/AML-3 (AML2 
and AML3 respectively) were used to investigate the effects of the NPMc mutation. These 
cell lines were established from the peripheral blood of AML patients and are commonly 
used in leukaemia research. Both cell lines are wild type for p53, but the AML3 cell line is 
heterozygous for NPMc. 
In order to determine whether the NPMc mutant contributes to cell death resistance, 
lentiviruses carrying GFP-tagged NPMc gene constructs were used to transduce AML2 
cells. As controls, GFP or GFP-tagged wild type NPM (wtNPM) were similarly expressed 
transduced. The correct subcellular localisations of the transgenes, nucleolar localisation 
of wtNPM and cytoplasmic localisation of NPMc, were visualised by laser scanning 
confocal microscopy (Figure 3.1A). Stable transductants were selected via blasticidin 
resistance, and GFP-positive cells were sorted from dead or non-fluorescing cells by 
fluorescence activated cell sorting (FACS). The levels of expression of the GFP-tagged 
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wild type or mutant NPM were found to be comparable by blotting the cell lysates with 
anti-GFP antibodies (Figure 3.1B). 
To investigate whether NPMc contributes to resistance towards cytotoxic-induced cell 
death, AraC (cytosine arabinoside, cytarabine), the mainstay chemotherapeutic agent used 
for treatment of AML, was used to induce cell death. AML2 cells stably transduced with 
GFP, GFP-tagged wtNPM or NPMc were treated with 5µM AraC (or DMSO as a control) 
for 24 hours. Cell death among GFP-positive cells was assayed using flow cytometry with 
Annexin V staining. Cells expressing GFP only were highly susceptible to AraC treatment 
(39.0% Annexin V positive cells), whereas cells expressing GFP-tagged NPMc showed 
greater resistance towards AraC (14.4% Annexin V positive cells, Figure 3.2A). Cells 
expressing GFP-tagged wtNPM exhibited a slight increase in cell death resistance (24.3% 
Annexin V positive cells), though it was not as significant as that seen in GFP-NPMc 
expressing cells. This demonstrated that the overexpression of NPM conferred resistance 
towards AraC-induced cell death, with the cytoplasmic mutant form of NPM giving the 
greatest amount of resistance. 
The effect of enhancing cell death resistance by expressing NPMc was also observed using 
other means to induce cell death. The death ligand, TRAIL, was used to induce cell death 
in THP-1 or HL-60 leukaemic cells transduced with GFP or GFP-tagged NPMc for 24 and 
48 hours. Cell death was analysed among GFP positive cells by enumerating condensed 
DAPI-stained nuclei (Figure 3.2B). As with the previous findings with AraC, the 
expression of NPMc diminished cell death induced by TRAIL. In THP-1 cells, the 
expression of NPMc decreased apoptosis from 35.5% and 29.5% after 24 and 48 hours 
respectively to 11.0% and 7.2%. Similarly, in HL-60 cells, NPMc expression decreased 
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apoptosis from 23.0% and 39.3% after 24 and 48 hours respectively to 3.5% and 16.7%. 
These findings suggest that NPMc prevents TRAIL- and chemotherapy-induced cell death 
in leukaemic cells.  
Despite numerous studies linking NPMc to cell death resistance, there are few reports that 
directly implicate the mutant protein in preventing cell death. Leong et al. [240] proposed 
that NPMc prevents cell death by inhibiting the progression of the caspase activation 
cascade. However, caspase inhibition only serves to delay the inevitable cell death that 
would follow, as demonstrated by the use of caspase inhibitors. Therefore, in order to block 
eventual cell death, signals upstream of the caspase activation cascade would need to be 
attenuated. The mitochondria serve as a major nexus for the intrinsic apoptotic pathway, 
with several pathways leading to the release of mitochondrial proteins to bring about 
caspase activation. As such, mitochondrial outer membrane permeabilisation (MOMP) has 
been considered as the point of no return in terms of apoptosis, and despite caspase 
inhibition, cell death is inevitable as other less-studied mechanisms take centre stage. 
Therefore, in order for cells to completely evade cell death, other means of cellular demise, 




















Figure 3.1 Expression and subcellular localisation of NPMc
AML2 cells transduced with lentivirus to express GFP, GFP-tagged
wtNPM or GFP-tagged NPMc. (A) The C-terminus sequence of
wtNPM contains the two tryptophan residues required for nucleolar
localisation, which is lost in the frame-shift mutation in NPMc, with
the new C-terminus amino acid sequence in red. The letters in bold
denote the key residues of the nuclear export signal (NES) consensus
sequence. Confocal microscopy shows the nucleolar and cytoplasmic
subcellular localisations of GFP-wtNPM and GFP-NPMc respectively,
and the immunoblot (B) shows comparable levels of expression of


















































































Figure 3.2 Expression of NPMc confers leukaemic cells resistance 
to AraC and TRAIL-induced cell death. 
(A). AML2 cells were transduced with GFP, GFP-tagged wtNPM or
GFP-tagged NPMc and were treated with AraC for 24 hours. Cell death
was quantified by Annexin V-stained cells among the GFP-positive
cells via flow cytometry. (n=3) (B). Leukaemic cell lines THP-1 and
HL-60 were transduced with GFP or GFP-tagged NPMc and were
treated with 300ng/ml TRAIL. Cell death was quantified by
enumerating condensed DAPI-stained nuclei among GFP-positive




3.2.2 NPMc expression upregulates autophagy 
In recent years, autophagy has been put in the limelight. Not only has it been implicated in 
association with cell death, it has also been found to be involved in promoting cell survival. 
This cytoprotective effect of autophagy was demonstrated in several studies, and the 
common theme is the removal of cellular contents which would otherwise ultimately lead 
to cell death, including mitochondria undergoing MOMP [241] and intracellular aggregates 
[242, 243]. Based on these observations, cytoprotective autophagy is an attractive 
c a n d i d a t e  b y  w h i c h  N P M c  p o s i t i v e  c e l l s  e v a d e  c e l l  d e a t h . 
The observation of autophagy can easily be made through the use of the autophagic marker 
microtubule associated protein 1 light chain 3 (henceforth referred to as LC3). Originally 
discovered as a subunit of microtubule associated proteins 1A and 1B, LC3 was later found 
to be homologous to the yeast autophagy protein ATG8. LC3 exists as a soluble form in 
the cytoplasm, termed LC3-I. During autophagy, LC3-I is conjugated to 
phosphatidylethanolamine via a series of ubiquitin-like steps involving ATG3 and ATG7, 
converting it to LC3-II and allowing its association with autophagic vesicles. LC3-II 
molecules are visible as puncta decorating autophagic vesicles and can be separated from 
the LC3-I form due to their higher electrophoretic mobility [244].  
In order to determine if NPMc affects autophagy, HEK293T cells were used for 
visualisation of LC3-II puncta. HEK293T cells were chosen instead of leukaemic cells 
because the latter have a low cytoplasm to nucleus ratio, making visualisation difficult. 
Furthermore, HEK293 cells are easily transfectable, thus allowing the use of RFP-tagged 
LC3 for fluorescent microscopy. As such, RFP-LC3-II would show up as red fluorescing 
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puncta in micrographs. Plasmids encoding GFP, GFP-wtNPM or GFP-NPMc were co-
transfected with plasmids encoding RFP-LC3 into HEK293 cells and visualised 24 hours 
post-transfection (Figure 3.3A). The mean number of puncta for GFP, GFP-wtNPM and 
GFP-NPMc expressing cells were 13.12, 20.75 and 27.36 respectively (Figure 3.3B). Cells 
expressing GFP-NPMc exhibited a higher level of RFP-LC3-II puncta compared to GFP-
wtNPM or GFP transfected cells, suggesting that NPMc contributes to increased levels of 
autophagy. As the increase in autophagy could be due to the overexpression of GFP-NPMc, 
chloroquine was used to block degradation of autophagic vesicles to assay for the 
accumulation of GFP-NPMc (Figure 3.3C). Unlike LC3-II, there was no accumulation of 
GFP-NPMc after chloroquine treatment, indicating that autophagy was not involved in the 
degradation of GFP-NPMc. In all, the results indicate that NPMc expression led to 





Figure 3.3 Expression of NPMc upregulates autophagy, though not
as a result of increased protein load.
HEK293T cells were co-transfected with RFP-tagged LC3 and either
GFP, GFP-tagged wtNPM or GFP-tagged NPMc. 24 hours post-
transfection, the cells were fixed and stained with Hoechst 33324. (A)
RFP-LC3 puncta, indicative of autophagic vesicles, in GFP positive
cells were visualised using laser scanning confocal microscopy (Scale
bar represents 20µm). (B) The number of RFP-LC3 puncta larger than
0.0225µm2 per cell was quantified. Studentised t-tests were performed,
with * and ** indicating p values less than 0.05 and 0.01 respectively.
(C) HEK293T cells transfected with GFP-NPMc were treated with
chloroquine (CLQ) for two hours 24hr post-transfection and














3.2.3 Cytotoxic stress induces autophagy in NPMc-expressing leukaemic cells 
While autophagy is a dynamic metabolic process that occurs in cells even at basal levels, 
its upregulation does not necessarily correspond to the prevention of cell death. As such, a 
cytotoxic trigger was employed to induce cell death to determine if the increase in 
autophagy in NPMc-expressing cells acts in a cytoprotective manner. When AML2 cells 
were exposed to the cytotoxic drug AraC, no apparent changes in autophagy, as measured 
by LC3-II levels, were observed (Figure 3.4). However, as autophagy is a dynamic process 
involving constant formation and degradation of autophagic vesicles, changes in 
autophagic regulation are not always reflected when visualising autophagy markers at a 
steady state. The use of inhibitors of autophagosome degradation would accumulate 
autophagic vesicles, hence allowing the visualisation of the increase or decrease in the 
amount of autophagy in the cell [245]. Therefore, chloroquine was used in conjunction 
with AraC to observe autophagic flux in AML cells. Chloroquine inhibits lysosomal 
acidification and prevents proteases from degrading autolysosome contents after 
lysosomes fuse with autophagosomes. 
As expected, the addition of chloroquine resulted in the accumulation of LC3-II in AML2 
cells expressing GFP, GFP-wtNPM or GFP-NPMc (Figure 3.4). However, upon addition 
of AraC to the chloroquine-pre-treated cells, both GFP and GFP-wtNPM expressing AML2 
cells showed decreased LC3-II levels, indicating a reduction in autophagosome formation 
(0.79 and 0.81 times respectively). Comparatively, GFP-NPMc-expressing AML2 cells 
exhibited the converse, with increased levels of LC3-II accumulation (1.82 times by 
densitometry) following cytotoxic treatment. This indicated that the expression of NPMc 
in AML cells brought about a shift from downregulation of autophagy to an upregulation 
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in response to cytotoxic stress, suggesting a mechanism by which NPMc altered autophagy 
signalling to favour increased autophagy.  
  
Figure 3.4 Cytotoxic stress by AraC induces autophagy in NPMc-
expressing cells
AML2 cells stably expressing GFP, GFP-wtNPM or GFP-NPMc were
pre-treated with 10µM chloroquine (CLQ) for 1 hour prior to cytotoxic
treatment with 5µM AraC for 3 hours. The cells were lysed with
sonication and immunoblotted with anti-LC3 antibodies. The formation
of the modified form LC3-II is indicative of autophagy. β-actin was
used as a loading control. The numbers indicate the fold-change of
LC3-II (normalised with β-actin) in chloroquine-pretreated cells with


































3.2.4 Autophagy inhibition abolishes cell death resistance in NPMc-expressing cells. 
Since autophagy is implicated in both cell death and cell survival, there is a need to discern 
whether the upregulation of autophagy in NPMc-expressing cells acts to mediate cellular 
demise or in a cytoprotective manner. This distinction can be made by inhibiting autophagy 
in the presence of cytotoxic stress. 3-methyladenenine (3MA) and wortmannin were used 
to inhibit autophagy initiation in the presence of AraC, and cell death was assayed by flow 
cytometric analysis of Annexin V staining (Figure 3.5). While AML2 cells expressing 
NPMc were resistant towards AraC treatment compared to the GFP- or wtNPM-expressing 
counterparts, the presence of 3MA sensitised NPMc-expressing AML2 cells towards 
AraC-induced cell death (Figure 3.5A). To minimise confounding results by the 
overexpression of NPMc, AML3 cells that endogenously harbour the NPMc mutation was 
used as a comparison to AML2 cells. Similarly, wortmannin was used to inhibit autophagy 
in the presence of AraC, and while AML3 cells were resistant towards AraC alone, this 
resistance was eliminated with the addition of wortmannin (Figure 3.5B). In summary, 
these data provide evidence that the upregulation of autophagy in NPMc-expressing cells 
serves a cytoprotective effect, thereby contributing to the cells’ resistance towards 
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Figure 3.5 Inhibition of autophagy abolishes NPMc-conferred cell 
death resistance upon treatment with AraC.
(A). AML2 cells stably expressing GFP, GFP-tagged wtNPM or GFP-
tagged NPMc were treated with 5µM AraC for 24 hours, in the absence 
or presence of the autophagy inhibitor 3-methyladenine (3MA, 10mM). 
Cell death was assayed using flow cytometry with Annexin V staining 
(n=3). * indicates p < 0.05 (B). NPM-wild type AML2 and NPMc-
mutant AML3 were treated with 5µM AraC for 12 and 24 hours, in the 
absence or presence of the autophagy inhibitor wortmannin (Wort, 









3.2.5 Molecular mechanisms of the role of NPM on autophagy 
With the establishment of the phenomenon of cytoprotective autophagy in NPMc-
expressing leukaemic cells, the next step would be to characterise the players involved in 
molecular signalling to link NPM to cytoprotective autophagy. The mammalian autophagy 
signalling pathway is a complex network mediated by multiple receptors and kinases that 
receive and bring about the formation of autophagosomes. Since autophagy serves as a 
major metabolic pathway, stimuli in the form of hormones (insulin, growth factors, for 
example) and low energy (high AMP levels, for instance) can trigger the initiation of 
autophagy. Also, other stimuli like oxidative stress can bring about autophagic responses.  
An important nexus central in the autophagy signalling pathway is the class III 
phosphoinositide 3-kinase (PI3K III) complex, comprising PI3K III (Vps34), Vps15, 
Beclin1, UVRAG, Bif-1 and Ambra1 [246]. The active complex generates 
phophotidylinositide 3-phosphate (PIP3) and is responsible for the initiation of autophagy 
vesicle nucleation, the beginnings of autophagosomes. This complex can be inactivated by 
the sequestration of Beclin1, mainly through the interaction with Bcl-2, or the highly 
homologous Bcl-xL. Therefore, the disruption of the Bcl-2 proteins from Beclin1 by Bcl-
2 homology 3 (BH3) domain-containing proteins, or posttranslational modifications of 
Bcl-2 would enable Beclin1 to form the PI3K III autophagy initiating complex.  
As a molecular chaperone, NPM has been implicated to interact with a large variety of 
proteins. One such protein is the pro-apoptotic Bcl-2 family member Bax [96]. Given that 
NPM interacts with Bax, we explored the possibility that NPM can interact with other 
members of the Bcl-2 family, particularly the ones central in the regulation of autophagy. 
59 
 
This led to the investigation of how NPM is implicated in the formation of the PI3K III 
autophagy initiating complex by the sequestration of Bcl-2. Based on how NPM can 
interact with Bax, we hypothesised that the presence of NPM in the cytoplasm (either wild 
type or the mutant NPMc) can interact and sequester Bcl-2, thereby allowing Beclin1 to 
form complexes with PI3K CIII (Figure 3.6). According to this model, we would expect 
that both wild type and mutant NPM can interact with Bcl-2, the availability of NPM in 
the cytoplasm forms the limit to such interactions. Therefore, since a large proportion of 
cellular NPM in NPMc exists in the cytoplasm, formation of the NPM-Bcl-2 complex 
would favour the formation of the PI3K III autophagy initiating complex. We would also 

















Figure 3.6 Hypothesised model of the role of NPM in autophagy. 
(A) At a basal level, there is a dynamic equilibrium between the 
interaction of Vps15, P13K III and Beclin1 (and others, like UVRAG 
and Bif-1, not shown) to form the autophagy initiation complex, and 
Bcl-2 and Beclin1 to disrupt complex formation. However, NPM is 
mostly nuclear and therefore does not participate actively in affecting 
the equilibrium. (B) However, with the translocation of NPM from the 
nucleus to the cytoplasm, either through increased shuttling to the 
cytoplasm in response to stimuli, or by massive exodus as in the case 
of NPMc mutation, NPM in the cytoplasm disrupts the equilibrium by 
sequestering Bcl-2, thereby derepressing Beclin1 and allowing the 
formation of the autophagy initiation complex, leading to increased 






3.2.6 NPM forms complexes with Bcl-2 
To establish that NPM interacts with Bcl-2, a GST pulldown assay was utilised. Equal 
amounts of recombinant GST, GST-wtNPM or GST-NPMc were immobilised on 
glutathione agarose beads and used to capture proteins from AML2 cell lysates. Both GST-
wtNPM and GST-NPMc were able to pull down Bcl-2 from the lysates, indicating that the 
mutation in NPMc did not affect Bcl-2 binding (Figure 3.7A). The supernatant from the 
pulldown with GST-wtNPM and GST-NPMc also showed a concomitant reduction in Bcl-
2. Interestingly, the assay was not able to pull down Bax, though it has been reported that 
NPM only interacts with activated Bax. In addition, immunoprecipitation with antibodies 
specific to NPMc was used to look for an endogenous interaction between NPMc and Bcl-
2 (Figure 3.7B). As in the GST pulldown, Bcl-2 co-immunoprecipitated with NPMc, 
indicating that NPMc interacted and bound to Bcl-2. Taken together, both wtNPM and 
NPMc were able to interact with Bcl-2. 
  
Figure 3.7 Interaction of GST-tagged wtNPM and NPMc with
Beclin1 and Bcl-2
(A) 30µg of AML2 cell lysate were incubated with 5µg glutathione-
agarose beads coated with GST, GST-tagged wtNPM, or GST-tagged
NPMc for 2 hours at 4oC. The beads were washed thrice with lysis
buffer before analysed in a Western blot with the indicated antibodies.
(B) Antibodies against NPMc were used to immuoprecipitate NPMc
from AML3 cell lysate. The immunoprecipitates were immunoblotted


















3.2.7 NPMc expression does not significantly affect formation of PI3K III-Beclin1 
autophagy initiation complex formation 
In order to determine if NPMc expression induces the formation of the PI3K III-Beclin1 
autophagy initiating complex, a co-immunoprecipitation assay was set up to compare the 
formation of the complex in NPMc-expressing cells and cells that harbour wtNPM. Beclin1 
was immunoprecipitated from lysates from AML2 cells expressing GFP, GFP-wtNPM or 
GFP-NPMc and the amount of PI3K III bound as a complex was examined (Figure 3.8A). 
However, the was no significant increase in PI3K III in the immunoprecipitates using 
lysates containing NPMc, indicating that NPMc overexpression could not bring about a 
significant change in this autophagy initiating complex formation. To test the hypothesis 
further to see if NPM could favour PI3K III-Beclin1 interaction and prevent Beclin1-Bcl-
2 complex formation, recombinant NPM was added to AML2 cell lysates and the PI3KIII-
Beclin1 or Beclin1-Bcl-2 complex formation was assayed by co-immunoprecipitation. 
Although the presence of recombinant NPM in the lysates did successfully disrupt Bcl-2 
and Beclin1 interaction, there was no concomitant increase in PI3K III-Beclin1 complex 
formation. Furthermore, the Beclin1-Bcl-2 interaction was only disrupted with excessive 
and non-physiological levels of 10µM recombinant NPM (Figure 3.8B). In conclusion, 
while there is evidence that the expression of NPM in the cytoplasm (in the form of NPMc 
mutation) can upregulate pro-survival autophagy, and that NPM can bind to Bcl-2, the 
mechanism of action may not necessary act through the central PI3K III-containing 
autophagy initiating complex.  
  
InputIP: Neg Bcln Bcln Neg Bcln Bcln Neg Bcln Bcln
GFP wtNPM NPMc




Figure 3.8 NPM did not significantly affect PI3K III-Beclin1
complex formation
(A) Co-IP was performed using non-specific IgG (Neg) or anti-Beclin1
IgG (Bcln) and cell lysates from AML2 cells expressing GFP, GFP-
wtNPM or GFP-NPMc, with or without 3hr AraC induction.
Immunoprecipitates were immunoblotted with the indicated antibodies.
(B) Beclin1 was immunoprecipitated with anti-Beclin1 antibodies (or
non-specific IgG as negative control) and assayed for co-
immunoprecipitated PI3K III or Bcl-2 in the presence of polyhistidine-






















3.3.1 Cell death resistance in NPMc-expressing cells 
Despite the identification of more than 50 mutations in NPM1 in AML, all mutations result 
in the loss of a nucleolar localisation signal by removal of W288 and W290 [247], or W288 
alone [248]. In addition, all mutations generate a novel NES motif, creating an additional 
site for Crm1-dependent nuclear export of the mutant proteins. Moreover, through 
heterodimerisation with wild type NPM, the strong additional NES of the mutant NPM 
draws the wild type protein out of the nucleus into the cytoplasm [249]. The outcome is 
common among the mutants: the aberrant and enforced cytoplasmic localisation of NPM 
[28].  
Here, we show that the expression of the cytoplasmic mutant NPMc results in resistance 
against cytotoxic insults in leukaemic cells. Not only does the endogenous expression of 
NPMc confer resistance, as seen in AML3 cells, but the exogenous expression of NPMc 
also gives rise to greater resilience in AML2 cells. Resistance towards cell death is one of 
the earliest hallmark a cell acquires to become cancerous, as observed in the overexpression 
of Bcl-2 in B-cell lymphoma [250]. As such, these observations directly implicate a role 
of NPMc in the development of leukaemia.  
Similar observations were made by other groups, such as the demonstration that NPMc 
positive AML cells can prevent ARF induction and downstream p53-dependent 
transcription in cells transformed by E1A [95]. Leong et al. [240] also demonstrated that 
NPMc expression rescued cell death induced by AraC and TRAIL, and that the knockdown 
of NPM resulted in the sensitisation of AML cells towards cell death. Comparable findings 
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were also made when NPM deoligomerisation induced by a small molecule inhibitor and 
RNAi of NPM sensitised NPMc-expressing cells towards AraC or ATRA induced cell 
death [251]. Taken together, these findings provide strong supporting evidence that NPMc 
expression does indeed protect leukaemic cells against cell death. 
3.3.2 Protective autophagy in leukaemia 
While there have been several observations that the expression of the mutant NPMc renders 
leukaemia cells resistant towards cell death, there have only been a few explanations to 
give an insight as to how the resistance is achieved. One prevalent hypothesis is the 
inhibition of the p53 signalling pathway. However, given that inactivation of p53 would 
result in genomic instability, NPMc+ AML cells mostly carry normal karyotypes. 
Moreover, the NPMc+ AML cell line AML3 were more resistant than wild type NPM 
expressing AML cell lines towards the specific p53-activating molecule nutlin-3 [252], 
suggesting that despite being wild type for p53, the mechanism of resistance likely acts 
downstream of p53 activation. 
Leong et al. [240] also reported that NPM can bind to and inhibit caspases-6 and -8, and 
that because of its displacement to the cytoplasm, the NPMc mutant is able to interact and 
sequester the two caspases. Not only do the activities of these caspases diminish with the 
expression of NPMc, the entire caspase activation cascade is inhibited. While this 
mechanism can account for a lack of caspase activity, it would not be able to explain the 
caspase independent cell death that would occur after mitochondria outer membrane 
permeabilisation [253, 254].  
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The observation of increased autophagy in cells undergoing cell death has led to the initial 
belief that autophagy is a mediator of cellular demise [255]. This was commonly termed 
as type II cell death, as opposed to type I or apoptotic cell death. However, opposing 
findings make it difficult to determine whether autophagy causes cell death, and in many 
cases rather than autophagy mediating cell death, what has been observed is more likely 
cell death accompanied by but not caused by autophagy [256]. Furthermore, the realisation 
that autophagy may act in a cytoprotective and pro-survival manner has introduced an 
alternate view where cell survival is actively promoted by the metabolic flux created by 
autophagy [234, 257, 258].  
Here, we demonstrate that the expression of NPMc led to an increase in autophagy. It was 
also observed that the exogenous expression of wtNPM increased the level of autophagy 
and imparted a modest level of resistance towards cell death, but not as significantly as that 
caused by the expression of NPMc. This could be attributed to an increase in transient 
cytoplasmic wtNPM following enforced overexpression.  
While the inhibition of autophagy has been found to increase chemotherapeutic response 
in many cancers including leukaemia [259-262], we show that inhibition of autophagy in 
NPMc-expressing cells abolishes NPMc-mediated cell death resistance, suggesting an 
upregulation of cytoprotective autophagy. Even though the results also suggest an 
interaction between Bcl-2 and NPM, this binding did not appear to have any effect on the 
PI3K III autophagy initiating complex. It is probable that NPMc affects autophagy 
signalling downstream of this complex, and further study is needed to determine the exact 
mechanism. Nonetheless, these observations support the notion that pro-survival 
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4 Chapter 4 – Inhibition of nuclear export in NPMc+ AML 
4.1 Introduction 
The aberrant cytoplasmic localisation of NPMc has been implicated to be one of the major 
causes of acute myeloid leukaemia. As reviewed in Chapter 1, the loss of NPM (both wild 
type and mutant) from the nucleus and its massive translocalisation to the cytoplasm can 
result in both its loss of nuclear function and gain in cytoplasmic capabilities. Given that 
the mutant and the wild type proteins differ only in the extreme C-termini, it is unsurprising 
that NPMc retains many of its original functions, including ARF interaction [99] and 
regulating centrosomal duplication [263]. Therefore, a prudent strategy in treating NPMc+ 
AML is the targeted relocalisation of the mutant protein back to the nucleus, where it can 
simultaneously regain its nuclear functions, as well as downregulate its cytoplasmic ones. 
The nuclear export of NPM is dependent on chromosome region maintenance 1 (Crm1, 
exportin-1), a member of the karyopherin β family of transport receptors [264]. Crm1 is 
effectively and potently inhibited by leptomycin B, but this drug was found to be highly 
toxic when used as a clinical therapeutic in Phase I trials, and no further trials were 
performed [265]. The mechanism of action of leptomycin B is the irreversible covalent 
binding of the small molecule inhibitor to a key cysteine residue in Crm1 that interfaces 
with the leucine rich NES of the target protein. The toxicity of leptomycin B can be 
attributed to the importance of Crm1 in the trafficking of a large number of proteins, 
including cell cycle regulators, transcription factors and RNA molecules [266, 267]. As 
such, although leptomycin B can effectively prevent cytoplasmic accumulation of NPMc, 
its use as a therapeutic is severely limited. However, making use of what is known about 
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the mechanism of action of Crm1 inhibitors, Karyopharm Therapeutics have developed a 
new generation of Crm1 export inhibitors. Like leptomycin B, these compounds 
irreversibly block Crm1 by specifically targeting the key cysteine residue (Cys528) in the 
NES-binding groove, but these compounds have been designed and optimised to show 
efficacy while reducing toxicity. It has been speculated that this may be because these 
smaller molecules permit a certain restricted level of nuclear export of some cargo proteins 
[268, 269]. As a result of this targeted design, these new generation Crm1 inhibitors exhibit 
tolerable toxicities compared to leptomycin B, and are effective in more than 20 
genotypically different colorectal cancer cell lines. 
The AML2 and AML3 cell lines can be effectively used to determine if nuclear export 
inhibition would diminish cell death resistance conferred by the expression of NPMc. As 
introduced in the previous chapter, AML2 cells are wild type for NPM, while AML3 cells 
are heterozygous for NPMc. Armed with these new generation of Crm1 inhibitors, we 
sought to determine if the Karyopharm compounds could effectively prevent cytoplasmic 
translocation of NPMc in AML. Also, we investigated the feasibility of using these new 





4.2.1 Karyopharm compounds prevent cytoplasmic localisation of NPMc and p53 
in AML 
Six Karyopharm compounds (KPTs), KPT-185, KPT-207, KPT-225, KPT-249, KPT-251 
and KPT-276, were obtained from Karyopharm Therapeutics. To establish their activity as 
a nuclear export inhibitor, NPMc-expressing AML3 cells were treated with the six KPTs 
and the subcellular localisation of NPMc was assayed by immunofluorescence using 
NPMc-specific monoclonal antibodies (Figure 4.1). Their ability to prevent cytoplasmic 
accumulation of NPMc was compared to leptomycin B. All six KPTs demonstrated the 
ability to prevent cytoplasmic accumulation of NPMc and restore its nucleolar localisation, 
as demonstrated by largely negative cytoplasmic staining and positive nuclear and 
nucleolar staining.  
It has been hypothesised that since NPM interacts with p53 [270], the expression of NPMc 
can cause cytoplasmic translocation of p53. As such, to determine if nuclear export 
inhibition can cause nuclear translocation of p53, a similar immunofluorescence was 
performed on AML cells treated with KPT-185 (Figure 4.2). Interestingly, while KPT-185 
could cause nuclear accumulation of p53 in AML2, only a portion of the NPMc-expressing 
AML3 cells showed nuclear translocation of p53.  
AML2 and AML3 cells treated with KPT-185, KPT-249 and KPT-276 were then separated 
into their nuclear and cytoplasmic fractions and the localisation of NPMc in AML3 (and 
wild type NPM in AML2) was analysed (Figure 4.3). Congruent to the 
immunofluorescence analysis, NPMc levels in AML3 increased in the nucleus and 
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concomitantly diminished in the cytoplasm in the presence of the KPT compounds. 
However, the nuclear localisation of wild type NPM in AML2 cells remained largely 
unaffected. Immunoblotting for p53 showed that the three KPT compounds induced p53 
upregulation, accounting for the presence of cytoplasmic and nuclear p53 detected by 
immunofluorescence as shown in Figure 4.2. Strikingly, while p53 levels increased slightly 
in AML2, its basal level of p53 was much higher than in AML3. This anomaly will be 
discussed in Chapter 5 of this dissertation. Overall, both the immunofluorescence and 



















Figure 4.1 KPT compounds prevent cytoplasmic localisation of
NPMc in AML3 cells
AML3 cells treated with indicated compounds for 24hrs were fixed and
stained with NPMc-specific antibodies. Nuclei were stained with DAPI







Figure 4.2 KPT compounds inhibit cytosolic localisation of p53
AML2 or AML3 cells treated with 100nM KPT 185 (or DMSO
vehicle) 24hr, were fixed and stained for p53 with DO-1 antibodies.










































































































Figure 4.3 KPT compounds prevent NPMc cytoplasmic
accumulation and induce p53 activation
AML2 (A) or AML3 (B) cells were treated with 100nM of the
indicated KPT compounds, or DMSO as a control, for 24 hours. The
cells were lysed by sonication and immunoblotted with the indicated
antibodies. Antibodies against wtNPM were used for the immunoblot





4.2.2 KPT-185 synergises with Mdm2 antagonist nutlin-3 
To determine if the KPT compounds could be used as a therapeutic agent against leukaemic 
cells, the effect of KPT-185 on apoptosis in AML cells was investigated. By itself, 100nM 
KPT-185 did not induce extensive cell death in either AML2 or AML3 cells, even after 48 
hours (Figure 4.4). We investigated whether the nuclear export inhibitor could act 
synergistically with other chemotherapeutic agents, especially in treating leukaemic cells 
that are resistant towards cell death. The commonly used anti-leukaemia drug AraC was 
used to induce cell death, and as expected, while it managed to cause massive apoptosis in 
AML2 cells, AML3 cells were resistant towards AraC (Figure 4.4A). However, there was 
a slight increase (12.7% after 48 hours) in cell death in AML3 when AraC and KPT-185 
were used in combination, though the effects are likely to be additive, rather than 
synergistic. Interestingly, KPT-185 rescued AML2 cells from AraC-induced apoptosis, 
suggesting a requirement for nuclear export to elicit programmed cell death.  
A more striking observation was made when nutlin-3 was used to induce apoptosis. Nutlin-
3 is a small molecule Mdm2 inhibitor that binds in the p53-binding pocket, preventing 
interaction with and degradation of p53, thereby allowing p53 activation, leading to cell 
cycle arrest, growth inhibition, and apoptosis [271]. Upon treatment with nutlin-3, AML2 
cells underwent apoptosis, whereas AML3 cells showed resistance towards the drug 
(Figure 4.4B). However, in the presence of KPT-185, nutlin-3 induced cell death in both 
AML2 and AML3 was increased. The combination of KPT-185 and nutlin-3 resulted in a 
synergistic increase in apoptosis (88.5% in AML3), compared to either drug alone (18.8% 
and 28.5% AML3 cell death for KPT-185 and nutlin-3 respectively), essentially abolishing 
nutlin-3 resistance in AML3 cells. 
Figure 4.4 KPT-185 synergised with nutlin-3 to cause cell death
AML2 or AML3 cells were treated with 100nM KPT-185, or DMSO as
a control, for 24 and 48 hours, in the presence and absence of 2.5µM
AraC (A) or 10µM nutlin-3 (B). Cell death was assayed by staining













































































Though the mechanisms by which NPMc expression imparts resistance towards cell death 
has yet to be completely understood, it is possible to use several approaches in inducing 
cell death in these chemotherapy-resistant cells. Just as inhibitors of autophagy can 
potentially be used to treat leukaemia (Chapter 3), nuclear export inhibition could also be 
used to augment established chemotherapeutic regimes, allowing patients with drug-
resistant leukaemias to respond well to treatment.  
The propensity of NPMc to be relocalised to the cytoplasm is primarily attributed to the 
additional NES in the mutated C-terminus, which Crm1 recognises and mediates nuclear 
export [247]. While the inhibition of nuclear export by the KPT compounds restores the 
nuclear localisation of the mutant protein, its appearance in the nucleoli are likely to be due 
to heterodimerisations with the wild type NPM, which retain the C-terminal tryptophan 
residues critical to nucleolar targeting [247]. It remains to be seen, however, whether the 
reestablishment of NPMc to the nucleus restores its functions as a wild type protein, 
especially its tumour suppressor roles in stabilising tumour suppressors like p53 [91], ARF 
[99] and Fbw7 [272] in the nucleolus. It would be of great interest to study the stability and 
activities of these tumour suppressors in NPMc-expressing cells following treatment with 
the KPT compounds.  
The second effect of Crm1 inhibition on NPMc is its loss from the cytoplasm. Although 
NPM is a predominantly nuclear protein, it nonetheless shuttles continuously between the 
nucleus and the cytoplasm as part of its normal function. The NPMc mutation effectively 
imparts a gain-of-function to its cytoplasmic functions, including inhibition of the caspase 
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cascade [240]. The removal of NPMc from the cytoplasm would remove the inhibition of 
caspases, therefore permitting caspase-mediated cell death. Furthermore, the role of NPMc 
in upregulating cytoprotective autophagy (Chapter 3) could be mitigated with the nuclear 
sequestration of NPM. These mechanisms could explain how the Karyopharm compounds 
sensitise AML3 cells towards cellular demise. 
As mutations in p53 are relatively rare in leukaemia compared to solid tumours, an 
effective strategy in treating leukaemia is the utilisation of the existing p53 dependent 
apoptotic pathway. Many of these cancers with wild type p53 typically have defects in the 
regulation of p53, most commonly involving mutations or overexpression of the p53-
negative regulator Mdm2 [273]. As such, approaches to disrupt the p53-Mdm2 interaction 
through molecular inhibition or Mdm2 downregulation have been studied, and perhaps the 
most successful outcome is the development of small molecule antagonists of p53-Mdm2 
interactions. Nutlin-3 is one such inhibitor that is shown to be selective and potent towards 
p53-Mdm2 interaction [271]. Therapeutic doses of nutlin-3 have been shown to exhibit 
cytotoxicity towards leukaemic cells while sparing normal cells [274-276]. Furthermore, 
unlike conventional chemotherapeutic drugs that work via genotoxic activation of the p53 
pathway, nutlin-3 has been shown to be non-genotoxic and exhibit comparable cytotoxicity 
without causing DNA damage that can lead to further genomic instabilities [277]. Currently, 
nutlin-3 is undergoing clinical trials and has shown great promise in the treatment of 
several tumours [278].  
While nutlin-3 effectively induced cell death in AML2 cells, AML3 cells exhibited 
resistance to treatment. Also, KPT compounds alone were able to induce p53 upregulation, 
though this response did not seem to elicit significant apoptosis. However, the addition of 
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KPT-185 to nutlin-3 synergistically resulted in significant apoptosis in AML3, presumably 
through a combination of p53 induction and inhibition of NPMc nuclear export. Such a 
combination in therapy would allow the use of low doses of KPT-185 and nutlin-3 in 
treating a large proportion of AML patients with the NPMc mutation, potentially limiting 




5 Chapter 5 – Activation of wild type p53 in AML 
5.1 Introduction 
The guardian of the genome p53 codes for a transcription factor central in responding to a 
myriad of stress stimuli, resulting in the induction of several genes to bring about cell cycle 
arrest, apoptosis or senescence [279]. Cancers with aberrations in p53 have either mutated 
p53, or have dysfunctional p53 regulation. The latter is commonly achieved through Mdm2, 
which is responsible for nuclear export of p53 [280] and targeting p53 for ubiquitin-
mediated proteasomal degradation [281]. Recent evidence implicate Mdm4, an Mdm2 
homologue, in the inactivation and degradation of p53 [282]. Despite a high level of 
homology with Mdm2 and the presence of a C-terminal RING domain, Mdm4 does not 
have any E3 ligase activity. It is, however, capable in suppressing p53 transcriptional 
activity by binding the p53 transactivation domain via its N-terminal domain [185, 283]. 
Also, unlike Mdm2, Mdm4 expression levels are not dependent on p53, though Mdm2 
targets Mdm4 and itself for proteasomal degradation [284]. Both Mdm2 and Mdm4 are 
mutually dependent on each other to bring about effective downregulation of p53 [285]. 
Mdm4 forms heterodimers with Mdm2 through their RING domains, and this stimulates 
the Mdm2 E3 ubiquitin ligase activity, allowing polyubiquitination of p53 [286]. 
Although more than 50% of solid tumours carry p53 mutations, p53 mutations are rare in 
leukaemias [93]. Instead, wild type p53 in leukaemias is frequently inactivated through the 
abnormalities in Mdm2, and as much as 50% of leukaemias are found to overexpress 
Mdm2 [222]. This block in p53 signalling contributes greatly to the resistance of leukaemic 
cells to apoptosis. An effective therapeutic strategy is the restoration of wild type p53 
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function, through the disruption of its interaction with its negative regulators. The use of 
nutlin-3, the selective and potent inhibitor of the p53-Mdm2 interaction, in the treatment 
of wild type p53 positive leukaemia is therefore potentially very rewarding [271, 287].  
Here, we examined an AML cell line, AML2, with high basal levels of wild type p53. 
Using this AML line as a model, we sought to understand the mechanics governing the 
constant maintenance of a large pool of wild type p53 without spontaneously undergoing 
cell cycle arrest or apoptosis, and demonstrate that the overexpression of Mdm4 is 
responsible for modulating p53 localisation, half-life and activity. 
5.2 Results 
5.2.1 Differential extraction efficiencies of cell lysis methods 
We noticed that there were discrepancies in preliminary experiments when Mdm2 
upregulation, one of the many indications of p53 induction, was not consistent between 
experimental repeats. Upon investigation, it was determined that the inconsistencies were 
due to cell lysis using the non-ionic detergent Triton X-100. Actinomycin D, KPT-185, 
MG132 and nutlin-3 were used to induce p53 to cause Mdm2 upregulation. In contrast to 
immediate cell lysis with SDS-containing buffer heated to 95oC, extraction by incubating 
cells in ice-cold buffer containing 1% Triton X-100 did not yield as much Mdm2 and p21, 
even when the same amount of lysate was used for SDS PAGE (Figure 5.1A). There were 
smaller bands observed in the immunoblot probed with anti-Mdm2 antibodies in lysates 
prepared with Triton-X100. The exact same cells lysed with hot SDS did not yield these 
smaller fragments, except for cells treated with the proteasome inhibitor MG132, which 
yielded smaller species, probably as a result of compensatory degradation mechanisms in 
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response to a blocked proteasome-mediated degradation pathway. In contrast, the β-actin 
loading control was not affected by differences in cell lysis methodology. 
To determine if the difference in Mdm2 recovered were not because the protein was 
insoluble with Triton X-100, the pellet obtained after clearing the Triton-soluble fraction 
was solubilised with hot SDS. As a reference the same amount of cells were lysed directly 
with hot SDS. Equal volumes of the Triton-soluble and –insoluble fractions, as well as the 
SDS-soluble lysate, were loading in an SDS PAGE and immunoblotted with anti-Mdm2 
antibodies (Figure 5.1B). There was little Mdm2 recovered from the Triton-insoluble 
fraction, and the addition of the Triton-soluble fraction did not yield equivalent amounts of 
Mdm2 compared to the SDS-soluble cell lysate. This indicated that the decreased yield of 
Mdm2 by lysing cells with Triton X-100 was not due to the inability of the detergent to 
solubilise Mdm2. 
Given that the differences in Mdm2 yield by Triton X-100 and SDS cell lysis was not due 
to solubility, and that Mdm2 and p21, but not actin, were affected by the difference in lysis 
methods, we asked if there was specific proteolytic degradation in the Triton-solubilised 
cell lysates, especially when 40kDa bands were observed in the Triton-soluble fractions. 
As Mdm2 contains caspase cleavage sites [288, 289], we investigated the possibility of 
caspase activity mediating the degradation of Mdm2. Caspase activity was inhibited using 
the pan-caspase inhibitor Q-VD-OPh in the presence or absence of p53-inducing nutlin-3, 
and the recovery of Mdm2 with the two lysis methods was compared (Figure 5.1C). 
Contrary to what was hypothesised, caspase inhibition did not result in an accumulation of 
Mdm2 recovered from the Triton-lysed cells, indicating that caspase cleavage was not 
responsible for the loss of Mdm2 obtained.  
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Both Mdm2 and p21 are degraded by ubiquitin-mediated proteasomal degradation [182, 
290]. To determine if the differences in protein extracted was due to residual proteasome 
activity in the Triton-solubilised cell lysates, MG132 was added to inhibit proteasomal 
degradation. As hypothesised, the addition of MG132 increased the amount of Mdm2 
recovered in the Triton-soluble fraction (Figure 5.1D), suggesting that proteins degraded 
by the proteasomal pathway are unstable in Triton-solubilised cell lysates. In summary, 
these observations indicate that several proteins, especially proteins with short half-lives 
like Mdm2 [291], are prone to degradation in Triton-solubilised cell lysates. In order to 
obtain unbiased results for analysis, cells henceforth were lysed with hot SDS instead of 
Triton X-100, or in the presence of proteasome inhibitors when denaturing conditions were 


























































































Figure 5.1 Differences in protein extraction efficiencies linked to 
protein degradation
(A) AML3 cells treated with DMSO, 2nM actinomycin D (ActD), 
100nM KPT-185, 10µM MG132 or 10µM nutlin-3 for 6 hours were 
lysed with ice-cold buffer containing 1% Triton X-100 or hot buffer 
containing 1% SDS and analysed by immunoblotting. (B) Equal 
amounts of AML3 cells treated 10µM nutlin-3 were lysed with ice-cold 
buffer containing 1% Triton X-100 or hot buffer containing 1% SDS. 
The Triton-insoluble fraction was collected and solubilised with the hot 
SDS buffer. Equal volumes of lysates were separated by SDS PAGE 
and immunoblotted for Mdm2. (C) AML3 cells treated with nutlin-3 or 
caspase inhibitor Q-VD-Oph were lysed as in (B) and separated by 
SDS PAGE. (D) AML3 cells treated with 10µM nutlin-3 (or DMSO) 
were lysed with Triton, with or without 10µM MG132 in the lysis
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5.2.2 AML2 cells are sensitive to nutlin-3, despite high basal levels of wild type p53 
We looked into the effects of nutlin-3 on AML cells by testing the sensitivities of three 
AML cell lines AML2, AML3 and MOLM13. All three cell lines were established from 
the peripheral blood of AML patients and are wild type for p53. A notable difference is 
that AML3 cells harbour the cytoplasmic mutant NPM, while AML2 and MOLM13 cells 
are wild type for NPM. Apoptosis was assayed by staining cells treated with nutlin-3 for 
24 and 48 hours with Annexin V and analysing them using flow cytometry (Figure 5.2). 
MOLM13 cells were extremely sensitive to nutlin-3, with almost all cells (92.3% and 99.2% 
after 24 and 48 hours) undergoing apoptosis with treatment of 10µM nutlin-3. AML2 cells 
were less sensitive compared to MOLM13 cells, exhibiting significant cell death 10µM 
nutlin-3 (45.8% and 72.6% after 24 and 48 hours). However, AML3 cells showed 
resistance towards nutlin-3, exhibiting only a relatively small percentage of apoptotic cells 
at 10µM nutlin-3 (11.3% and 21.9% after 24 and 48 hours), even lower compared to AML2 
cells treated with 2µM nutlin-3 (16.5% and 25.3% after 24 and 48 hours). Despite having 
wild type p53, the three cell lines responded differently to nutlin-3 treatment.  
In order to understand this discrepancy, we examined the effect of nutlin-3 on p53 and p53-
regulated expression. Flow cytometry of p53 staining in the three AML cell lines showed 
a higher level of p53 in untreated AML2 cells, with p53 levels increasing even higher after 
nutlin-3 exposure (Figure 5.3). In contrast, AML3 and MOLM13 displayed low basal 
levels of p53, only increasing upon nutlin-3 induction. Interestingly, while high levels of 
wild type p53 is associated with cell cycle arrest and apoptosis, the high basal levels of p53 
observed in untreated AML2 did not result in cell cycle arrest and apoptosis. To ensure that 
the p53 in these AML cell lines was wild type and functional, the three cell lines were 
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treated with nutlin-3 and Mdm2 protein upregulation, an indication of p53 activity, was 
observed (Figure 5.4A). In addition, p53-regulated genes like Mdm2, p21 and NOXA were 
upregulated at the RNA level in response to nutlin-3 induction in AML2 and AML3 cells 
(Figure 5.4B). The abnormal level and activity of p53 in AML2 cells could also be a result 
of aberrations in p53 negative regulators, chief among them are Mdm2 and Mdm4. 
Sequencing of cDNA from AML2 cells revealed that there were no mutations in either 
Mdm2 or Mdm4 (data not shown).  
To look for other means of Mdm2 deregulation, we examined the effect of ATM kinase on 
Mdm2, where ATM kinase-mediated phosphorylation of S395 inhibits the Mdm2-
mediated degradation of p53 [292]. The ATM inhibitor KU-55933 was used to determine 
if the high level of p53 was due to unchecked ATM kinase activity. Although treatment 
with the ATM inhibitor (ATMi) downregulated p53 levels in AML3 cells, the p53 levels 
in AML2 were largely unchanged (Figure 5.5A). This was despite the expected outcome 
of ATM inhibition: preventing the upregulation of Mdm2 and p21 upon nutlin-3 induction. 
Unphosphorylated Mdm2 actively mediates p53 nuclear export and degradation, thereby 
preventing p53-dependent transcription, whereas ATM-mediated phosphorylation of 
Mdmd2 promotes p53 nuclear accumulation and stability. Based on the findings here, the 
high basal level of p53 in AML2 was not due to hyperactivity of ATM kinase. 
Similarly, we examined another critical regulator of Mdm2, the tumour suppressor ARF. 
ARF binds to the acidic region of Mdm2 and inhibits p53 ubiquitination and degradation 
[211], and defects in ARF expression are frequently observed in cancers retaining wild 
type p53 [213]. However, there are no significant differences in ARF expression between 
AML2 and AML3, indicating that ARF was probably not responsible for the accumulation 
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of p53 (Figure 5.5B). In addition, we looked into a few of the ubiquitin specific proteases 
(USPs) that are known to affect p53. USP5 deubiquitinates p53 [293], while USP2a acts 
on Mdm2 [294], and differences in the levels of the two proteases can affect p53 levels. 
Regardless, there were no observable differences in the protein levels of these two USPs, 
suggesting that they are not involved in mediating p53 accumulation (Figure 5.5B). 
Mdm2 levels and response in AML2 cells were similar with AML3 cells, albeit at a lower 
level (Figure 5.4A). However, unlike Mdm2, the Mdm4 levels in AML2 cells were greater 
compared to AML3 cells, and this remained high upon treatment (Figure 5.4A, Figure 
5.5A). Comparatively, the Mdm4 levels in AML3 were lower and dropped rapidly upon 
drug treatment. Given that Mdm4 is known to bind and sequester p53 [295], and that the 
overexpression of Mdm4 is exploited by several cancers to deregulate p53 function [296-
298], the high and stable level of Mdm4 is a likely candidate responsible for the high basal 
p53 in AML2. 
Immunoblotting for Mdm4 revealed two immunoreactive species of Mdm4, one at the 
predicted 64kDa and the smaller one at 50kDa (Figure 5.5A). While the predicted Mdm4 
protein was degraded upon drug treatment, the smaller protein remained relatively stable. 


































Figure 5.2 Differential sensitivities of AML cell lines towards
nutlin-3
AML2, AML3 and MOLM13 cells were treated with 2µM or 10µM
nutlin-3 for 24 or 48 hours. The cells were stained with Annexin V-Cy5




















Figure 5.3 High basal and nutlin-induced p53 levels in AML2 cells
AML2, AML3 and MOLM13 cells treated with 10µM nutlin-3 for 0, 2,
4, and 8 hours were stained with mouse anti-p53 (DO-1) primary
antibodies (or mouse normal IgG as a negative control) and goat anti-
mouse Alexa488 secondary antibodies. The p53 levels in the cells were





























Figure 5.4 Induction of p53 response in AML cell lines following
nutlin-3 treatment
AML2, AML3 and MOLM13 cells were treated with 10µM nutlin-3
for the indicated durations. (A) The cells were lysed and
immunoblotted with the respective antibodies. (B) RNA was harvested
from AML2 and AML3 cells treated with 10µM nutlin-3 for 0, 2, 4, or
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Figure 5.5 High levels of p53 in AML2 were not due to ATM kinase
activity, overexpression of USPs, or elevated ARF levels.
(A)AML2 and AML3 cells were treated with 10µM nutlin-3 for the
indicated durations in the presence or absence of ATM kinase inhibitor
(ATMi) KU55933 for 4 hours. The cells were lysed and immunoblotted
with the respective antibodies. (B) AML2 or AML3 cells were treated
with 10μM nutlin-3 or DMSO, in the presence or absence of nuclear
export inhibitor KPT-185 for 4 hours before harvesting for cell lysis.






5.2.3 Wild type p53 in AML2 is stable but inactive at physiological conditions 
To understand the mechanism behind which wild type p53 in AML2 cells is elevated at a 
basal level, we tracked the amounts of p53, Mdm2 and Mdm4 present in both AML2 and 
AML3 cells at different intervals. The inhibitor of translation cycloheximide (CHX) and 
the proteasome inhibitor MG132 were used to offer insights on the half-life and 
ubiquitination of the proteins respectively. Compared to AML3, the p53 in AML2 was not 
only more abundant, but also exhibited a longer half-life, evident after CHX treatment 
(Figure 5.6A). Further, there was a greater amount of accumulation after proteasomal 
inhibition, indicating that there was a higher basal level of expression compared to AML3, 
where p53 hardly accumulated. The combination of CHX and MG132 accurately showed 
the steady state level of p53 in the two cell lines, potentially ruling out the involvement of 
other non-proteasomal degradation pathways.  
There were little differences between the two cell lines in terms of Mdm2 levels and 
stability (Figure 5.6B). At basal level, both AML2 and AML3 expressed low levels of 
Mdm2, given the Mdm2-p53 negative feedback loop. However, there were marked 
differences when comparing Mdm4 in the two cell lines (Figure 5.6C). Although both cell 
types expressed stable levels of Mdm4 in the absence of drug treatment, the levels in AML2 
were significantly higher than that in AML3. This reinforced the observation of elevated 
Mdm4 in AML2 cells. 
A measure of p53 stability and Mdm2/Mdm4 activity can be observed by pre-treatment 
and withdrawal of nutlin-3 [299]. CHX and/or MG132 were added to the cells after nutlin-
3 withdrawal to chart degradation and accumulation. Cells treated with the Mdm2 
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antagonist accumulate p53 and p53-responsive gene products rapidly, and the withdrawal 
of nutlin-3 reverses the upregulation, resulting in rapid degradation. Treatment with nutlin-
3 resulted in massive upregulation of p53, but, unlike in AML3, the p53 in AML2 was 
sustained at a high level (Figure 5.6E). This observation was emphasised with the use of 
CHX to inhibit protein synthesis, with p53 in AML3 diminishing rapidly, while the p53 in 
AML2 remained high. The use of MG132 also showed that p53 in AML3 cells was highly 
ubiquitinated, exhibiting greater levels of polyubiquitinated species of p53 compared to the 
p53 in AML2. This would explain the rapid loss of p53 in AML3 cells, as polyubiquitinated 
p53 were rapidly degraded in proteasomes. Interestingly, the combination of CHX and 
MG132 suggested that in AML2 cells only newly synthesised p53 underwent 
ubiquitination. This implies that there was a static pool of p53 in AML2 that was unaffected 
by degradation. 
Mdm2 in both cell lines behaved as expected after nutlin-3 withdrawal (Figure 5.6F). The 
half-lives of Mdm2 in both AML2 and AML3 were similar, and the level of ubiquitination 
were comparable. However, the levels of Mdm4 between the two cell lines were different, 
with Mdm4 in AML3 being rapidly degraded (Figure 5.6G). On the other hand, Mdm4 
levels in AML2 remained steady throughout the entire interval, even in the presence of 
CHX and/or MG132.  
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Figure 5.6 Excessive Mdm4 correlates to increased p53 stability in
AML2. AML2 or AML3 cells were treated with 10μM nutlin-3 or
DMSO for 4 hours before replacing with fresh media supplemented
with DMSO, 10μg/ml cycloheximide (CHX), 10μM MG132, or both
CHX and MG132. Cells were harvested every 15 minutes and
immediately lysed in 95oC SDS lysis buffer. The lysates were
sonicated, separated in SDS-PAGE, and immunoblotted for (A, E) p53,




5.2.4 Stability of p53 is determined by ratio of p53-Mdm2 to p53-Mdm4 interactions 
In order to determine whether the stability of p53 in AML2 was conferred by sequestration 
by high levels of Mdm4, we sought to map the interactions between p53 and Mdm2, and 
p53 and Mdm4. An ELISA using immobilised anti-p53 (Bp53 10.1) antibodies was used, 
recognising and binding p53 at the C-terminus, away from the N-terminal Mdm2/Mdm4 
binding site. Captured complexes in cell lysates from AML2 or AML3 cells, treated or 
untreated with nutlin-3, were detected using in a sandwich ELISA. As expected, the 
amount of p53 captured in the assay corresponded to the amount of p53 in each cell line, 
with high basal levels of p53 in AML2 and low levels in AML3, and both increased in 
response to nutlin-3 treatment (Figure 5.7A). The ELISA also showed that the p53 in 
AML3 cells were mostly complexed to Mdm2 (Figure 5.7B), while the p53 in AML2 cells 
were mostly bound with Mdm4 (Figure 5.7C). This suggested that while p53 in AML3 had 
the propensity to be bound to Mdm2 and therefore subsequently degraded, p53 in AML2 
were bound to Mdm4 instead, and this interaction prevents p53 degradation as well as p53 
activity. 
To reaffirm the findings of a higher level of p53-Mdm4 interaction in AML2, a proximity 
ligation in situ assay (PLISA) for the interaction was performed (Figure 5.8). As each 
PLISA spot corresponds to an interaction event, there was a greater amount of p53-Mdm4 
interaction in AML2, with or without nutlin-3 treatment. In contrast, the p53-Mdm4 
interaction in AML3 was exceedingly low, and only slightly increased in response to 
nutlin-3 treatment. A similar response was observed in MOLM13 cells, except for a greater 
increase in interactions after nutlin-3 exposure. It is interesting to note that in AML2, most 
of the interactions occur outside the nucleus in the cytoplasm. This observation reinforces 
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the hypothesis that Mdm4 sequesters and inactivates p53 by localising it in the cytoplasm, 
as observed by the presence of p53 in AML2 cytoplasm (Figure 4.3), as well as the findings 






























































Figure 5.7 p53 in AML2 binds preferentially to Mdm4 rather than
Mdm2, with or without nutlin-3 treatment. AML2 or AML3 cells
were treated with 10μM nutlin-3 or DMSO for 4 hours being harvested
for cell lysis. The indicated amounts of cell lysates were added to
ELISA plates coated with anti-p53 (Bp53 10.1) antibodies. Detection
of the indicated proteins complexed with captured p53 was achieved
using antibodies (HRP conjugated or with HRP conjugated secondary
antibodies) specific to p53 (A), Mdm2 (B) and Mdm4 (C). The graphs
depict the mean absorbance of three independent experiments with
95% confidence interval.
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Figure 5.8 p53 in AML2 binds to Mdm4, with or without nutlin-3
treatment. AML2, AML3 or MOLM13 cells were treated with 10μM
nutlin-3 or DMSO for 4 hours fixation and permeabilisation. PLISA
was performed using the Duolink kit according to manufacturer’s
recommendations and visualised with confocal microscopy.
Micrographs show the maximum intensity projection of 13 z-stacks,












5.2.5 Reduction of Mdm4 caused apoptosis in AML2 
To test the hypothesis that Mdm4 is responsible for the accumulation and inactivation of 
p53 in AML2 cells, siRNA against Mdm4 (siMdm4) was employed. Figure 5.9A 
demonstrated the successful knockdown of Mdm4 in AML2 and AML3 cells transfected 
with siMdm4, compared to the control using a non-targeting siRNA (siCtrl). Compared to 
AML3 cells, siMdm4-transfected AML2 cells displayed a decrease in cell viability 24 
hours post-transfection, indicating that Mdm4 is required to prevent cell death in AML2 
(Figure 5.9B). This drop in cell viability corresponded to an increase in PARP cleavage, 
implying caspase-mediated apoptosis (Figure 5.9A). Put together, the results suggest a 
reduction of the high levels of Mdm4 brought about the reduction of inhibition of p53 in 
AML2, leading to apoptotic signalling and cell death.  
Upon closer investigation on the effect of Mdm4 knockdown on p53 in AML2, the loss of 
Mdm4 did not result in the relocalisation of p53. Nuclear and cytosolic fractionation of 
AML2 cells transfected with siMdm4 did not significantly reduce cytosolic p53 levels, nor 
did it bring about its nuclear accumulation (Figure 5.9C). Moreover, knockdown of Mdm4 
alone did not result in the upregulation of the p53-responsive proteins Mdm2 and p21. 
While this does not rule out the possibility of the p53-dependent apoptotic gene 
transcription, the results seem to suggest a non-transcriptional role of the derepressed 
cytoplasmic p53 in AML2, or an unknown tumour suppressor that is also sequestered by 
Mdm4. Nonetheless, the loss in cell viability in response to Mdm4 reduction demonstrated 
the need for Mdm4 to maintain the high levels of p53 observed in untreated AML2 cells. 
  
Figure 5.9 Knockdown of Mdm4 induced PARP cleavage and cell
death in AML2, but not in AML3. (A) AML2 or AML3 cells
transfected with non-targeting siRNA (siCtrl) or siRNA against Mdm4
(siMdm4) for 24hr before treatment with 10µM nutlin-3 (or DMSO)
for 4hr, and blotted for the indicated proteins. (B) Cell viability of
AML2 and AML3 cells 24hr post-transfection with siCtrl or siMdm4,
as assayed by PI exclusion (n=3). * indicates p < 0.05 (C)
Nuclear/cytosolic fractionation of AML2 cells treated as in (A)
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Cancers that retain wild type p53 often carry mutations in regulatory genes that dampen 
p53 activity, effectively creating phenotypes similar to p53 mutations. Many of these 
mutations affect the stability and degradation of p53, governing the amount and/or 
localisation of p53 in the cancer cell. These mechanisms include Mdm2 overexpression, 
[300], ARF ablation [301], loss of PTEN expression [302], or p53 cytoplasmic 
sequestration [303]. Here, we show that a leukaemia cell line, AML2, carries high basal 
levels of wild type p53, and an amplified level of Mdm4 effectively binds to and inhibits 
p53 activity.  
High p53 levels in cells are frequently associated with cell cycle inhibition and apoptosis, 
and it would be seemingly paradoxical to observe high wild type p53 levels in actively 
dividing cancer cells. However, high wild type p53 expression levels have been observed 
in melanomas [304] and testicular cancers [305], and here, we report that a high level of 
wild type p53 is also detected in AML, as demonstrated in the AML2 cell line.  
Further investigation of the p53 in AML2 revealed that it is mostly cytoplasmic and bound 
to Mdm4. While Mdm4, together with Mdm2, is responsible for the ubiquitination and 
subsequent degradation of p53 [306], Mdm4 overexpression was previously reported to 
inhibit p53 activity by direct binding, sequestering the tumour suppressor in the cytoplasm, 
outcompeting Mdm2-p53 interaction and protecting p53 against proteasomal degradation 
[185, 295, 307, 308]. This coincides with the observations reported here that p53 was kept 
inactive in the cytoplasm at high levels by interactions with Mdm4. Although high Mdm4 
levels have been reported in melanomas [298], retinoblastoma [297], head and neck 
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squamous cancers [309], the high levels of both p53 and Mdm4 have not been described 
until now. Also, unlike in systems where Mdm4 had been exogenously introduced [310-
312], here we demonstrate that endogenously high levels of Mdm4 can effectively inhibit 
p53 activity and sequester it in the cytoplasm. 
In the pulse chase experiments, it was observed that only nascent p53 was ubiquitinated in 
AML2 cells (Figure 5.6E). As p53 in AML2 was mostly bound to Mdm4 but not Mdm2, 
the lack of p53 ubiquitination could be due to Mdm4 out-competing Mdm2 for p53 binding, 
preventing Mdm2 from ubiquitinating p53. This would also explain the increased stability 
and longer half-life of p53 observed in AML2 cells. Similarly, the high levels of Mdm4 
would also prevent Mdm2-mediated ubiquitination and subsequent proteasomal 
degradation of Mdm4, allowing the accumulation of Mdm4 in AML2 cells. The 
mechanism by which high levels of Mdm4 leads to high, stable levels of p53 is summarised 
in Figure 5.10. These observations highlight the importance of the stoichiometry of p53, 
Mdm2 and Mdm4 in maintaining their stability and degradation. 
Unlike model studies where Mdm4 overexpression blocked nutlin-induced apoptosis [310, 
311], the high levels of Mdm4 did not confer such resistance in AML2 cells. AML2 cells, 
while being more sensitive than AML3 cells, did not exhibit rapid cell death compared to 
MOLM13 cells. It is speculated that nutlin-3 prevents the degradation of newly-synthesised 
p53, thereby allowing the accumulation of p53 beyond what can be sequestered by Mdm4 
(Figure 5.11A). Nonetheless, the loss of cell viability in response to the knockdown of 
Mdm4 indicated that Mdm4 did indeed prevent cell death in AML2 cells. Since the 
precarious balance of Mdm2 and Mdm4 determines p53 stability and activity, it is feasible 
that disruption of Mdm2-p53 interaction by nutlin-3, in a cell ‘addicted’ to Mdm4 as an 
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oncogene, was sufficient to increase p53 levels beyond what can be sequestered by Mdm4, 
leading to apoptosis.  
The knockdown of Mdm4 by siRNA in AML2 cells resulted in cell death characterised by 
PARP cleavage. p53 nuclear relocalisation was not observed and the p53-dependent genes 
p21 and Mdm2 were not upregulated, suggesting that the release of p53 from its inhibition 
by Mdm4 led to cell death in a p53 transcription-independent manner (Figure 5.11B). 
Besides the transcriptional activation of pro-apoptotic genes like PUMA, NOXA and Bax, 
the stress-induced cytoplasmic and mitochondrial accumulation of p53 was found to lead 
to the direct activation of Bax and/or Bak [172, 313]. These pro-apoptotic members of the 
Bcl-2 family oligomerise and form pores in the mitochondria outer membrane, triggering 
the intrinsic apoptotic caspase cascade. This p53-dependent role in apoptosis was found to 
be present when p53 nuclear translocation was prevented [172] and when transcription was 
inhibited [314], and the activation of pro-apoptotic proteins by p53 was found to precede 
p53-activated transcription [315]. Further investigation led to the discovery that p53 can 
bind Bcl-2 [316] and Bcl-xL [317], preventing their anti-apoptotic activities. However, 
there are some discrepancies in the p53 transcription-independent role in apoptosis. 
Transcription-independent, p53-mediated apoptosis seems to only occur in some cell types 
but not others, and interactions with Bcl-2 family members like Bcl-xL or Bcl-2 are 
electrostatic and may be non-specific. Though the observations here suggest the 
involvement of p53 transcription-independent activity, more work must be done to directly 
implicate p53 in inducing cell death without transcription. 
Another possibility of apoptosis without p53 transcriptional activation is the involvement 
of another tumour suppressor protein that is also bound to and inactivated by Mdm4 (Figure 
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5.11B). This unknown protein may be a BH3-only protein, such as Bid or Bad, that can 
lead to mitochondria outer membrane permeabilisation when interaction with Mdm4 is lost, 
ultimately leading to apoptosis. Alternatively, the unknown protein could be a transcription 
factor that can be sequestered by high levels of Mdm4, and the release from sequestration 
can lead to transcription of pro-apoptotic genes, or repression of anti-apoptotic genes. 
Regardless, further work is required to isolate, identity and function of this unknown factor, 

























Stable cytosolic pool of p53
Figure 5.10 Ubiquitination of p53 by Mdm2 and Mdm4, and
sequestration of p53 by Mdm4. (A) Schematic representing p53
ubiquitination and degradation mediated by Mdm2 and Mdm4. Mdm2
binding results in p53 nuclear export and monoubiquitination, and
binding of p53 to Mdm2/Mdm4 heterodimer leads to
polyubiquitination and subsequent proteasomal degradation. (B)
Increased levels of Mdm4 in AML2 cells result in the sequestration of
p53 by preventing Mdm2 from ubiquitinating p53. Meanwhile, newly




























Stable cytosolic pool of p53
Figure 5.11 Effects of nultin-3 and Mdm4 RNAi on p53 activity in
AML2 cells. (A) Schematic representation of p53 activation by nutlin-
3. The stable pool of p53 is maintained by high Mdm4 levels, while
nutlin-3 halts nascent p53 degradation and allows its activation. (B)
RNAi of Mdm4 destabilises the cytosolic pool of p53 from its
sequestration by Mdm4, allowing p53 activity, such as the activation of
mitochondria outer membrane permeabilisation. Alternatively, the loss













Immunoblotting of the AML cell lysates with anti-Mdm4 antibodies revealed the presence 
of two reactive bands, one at approximately 64kDa, corresponding to full length Mdm4, 
and another at approximately 50kDa (Figure 5.9C). The 64kDa band is only observed in 
the cytosolic fraction, whereas the 50kDa band is predominantly nuclear. Since siMdm4 
knocked down both the larger and the smaller antibody-reactive proteins, the 50kDa band 
is unlikely to be a non-specific antibody target. Both Mdm2 and Mdm4 have a number of 
splice variants and can undergo extensive post translational modifications, the identity of 
the 50kDa protein could correspond to an Mdm4 isoform or modification. Mass 
spectrometry of the 50kDa protein would yield more insights to its identity, and depending 
on the modification, could yield greater insights into the role of Mdm4 in p53 localisation, 
stability and degradation. 
Anti-leukaemia chemotherapeutic drugs like AraC, etoposide and doxorubicin traditionally 
target DNA replication because of the rapid proliferation of leukaemia cells. However, 
these drugs also adversely affect numerous other rapidly dividing cell types, forming the 
basis of detrimental side effects. Treatment of leukaemia therefore is a balance of 
destroying the majority of leukaemic cells while killing as few normal cells as possible. 
These drugs are also genotoxic in nature, introducing the possibility of inducing further 
mutations that potentially generate other cancers, or even result in the induction of 
chemoresistance in the existing one. In fact, a major cause of AML is the use of cytotoxic 
drugs previously used to treat other forms of cancer. As a specific inhibitor of Mdm2-p53 
interaction, nutlin-3 offers advantages over traditional chemotherapeutic drugs in that, at 
optimal doses, its apoptotic effect is selective for tumour cells while normal cells undergo 
reversible cell cycle arrest [274]. Moreover, since the mechanism of action does not involve 
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DNA intercalation or damage, nutlin-3 is non-genotoxic [277]. Hence, the use of nutlin-3 
in a wild type p53 cancer like AML would be extremely suitable.  
The differential response of AML cells to nutlin-3 demonstrate the need to understand the 
underlying causes of resistance. Nutlins are currently undergoing clinical trials, and the 
efficacy of nutlins should not be dismissed entirely in cancers refractory to nutlin treatment. 
Given that there is evidence of Mdm4 overexpression in AML, combinatorial treatments 






6.1 Alternatives ways to induce cell death in AML 
The goal of chemotherapy is to kill the rapidly dividing cancer cells that proliferate 
unchecked in a patient’s body. For the more than 40 years the treatment of AML has 
involved the use of anthracyclines and cytarabine as chemotherapeutic agents. As these 
drugs are primarily inhibitors of nucleic acid synthesis, their main targets are cells that are 
rapidly proliferating. Unfortunately, besides leukaemic cells, many other cell types in the 
human body are continuously dividing for normal function, including skin cells and cells 
lining the gastrointestinal tract. Furthermore, anthracyclines and cytarabine are known to 
exhibit cardiotoxicity and cerebellar toxicity respectively, both of which greatly increase 
the risk of organ failure in AML patients undergoing induction and consolidation therapy. 
There is therefore a need to improve on the ways to treat AML, beyond optimising the 
dosages and making small improvements to the same class of cytotoxic drugs. 
The idea of targeted therapy is not new. In 1971, the use of oestrogen receptor antagonist 
tamoxifen (then called ICI46474) was reported to have comparable efficacies in breast 
cancer patients as hormone therapy, the mainstay treatment regime at that time, but with 
substantially lowered incidences of severe side effects [318]. Since then, armed with the 
increasingly growing pool of knowledge of the pathologies of different types of cancers, 
numerous advances have been made that extend the use of targeted therapy to other types 
of cancers, including chronic lymphocytic leukaemia, non-small cell lung carcinoma, and 
metastatic colon cancer. In many cases, the rate limiting factor of developing targeted 
112 
 
therapies to specifically act on cancer cells but have limited impact on normal cells is the 
lack of understanding of the diseases.  
The aim of this study is to investigate the use of targeted therapy in the treatment of AML. 
Specifically, two non-exclusive categories of AML were put to the question: AML with 
NPMc, which account for a third of all AML, and AML that are wild type for p53, which 
can account for up to 85% of all AML cases.  
6.1.1 Inhibition of autophagy as a therapeutic strategy for NPMc+ AML 
In order to determine which molecular pathway is suitable for targeted therapy, the basis 
of leukaemogenesis in NPMc positive AML was studied (Chapter 3). A major hallmark of 
cancer is the resistance towards apoptosis, and studying how AML cells escape this tumour 
suppressive mechanism is central in designing approaches in treating the disease. Firstly, 
we observed that in cells expressing NPMc, autophagy, a cellular process by which 
macromolecules and organelles are isolated and degraded, was upregulated. In NPMc-
expressing cells, this upregulation was associated with the presence of cytotoxic stimuli, 
as observed with the use of AraC. While autophagy can serve to function in both pro- and 
anti-survival mechanisms, the autophagy upregulated in NPMc-expressing cells was found 
to be pro-survival, since the inhibition of autophagy heightened AraC-induced cell death. 
This was especially so for AML3 cells, which endogenously express NPMc and are 
reflective of NPMc positive AML. AML3 cells were particularly resistant towards AraC 
treatment, exhibiting a minimal amount of apoptosis. However, with the addition of 
inhibitors of autophagy, the level of apoptosis in AML3 increased significantly, indicating 
the importance of autophagy in preventing cell death in these cells. 
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We sought to uncover the molecular pathways linking NPMc to autophagy, but we failed 
to obtain conclusive evidence that NPMc is implicated directly in the autophagy signalling 
pathway. Nonetheless, though we did not find any associations between the mutant protein 
and the Beclin-1/PI3K III autophagy initiating complex, NPMc could still be involved in 
other alternative means to achieve increased autophagy. Regardless, we were able to 
demonstrate that targeting cytoprotective autophagy may be a viable means to treat AML, 
and synergistic use of autophagy inhibitors and the current, well-established 
chemotherapeutic agents may achieve better efficacies and reduced side effects at treating 
NPMc positive AML. 
6.1.2 Nuclear export inhibitors in the treatment of NPMc+ AML 
The mutation of NPM in NPMc positive AML results in the aberrant cytoplasmic 
localisation of NPM in the cell, and this has been hypothesised to contribute to 
leukaemogenesis. The wild type and the mutant protein differ mainly in their C-termini, 
and since the rest of the protein is unchanged, NPMc could still bind to physiological 
interacting partners and retain the functions as in the wild type protein, such as ARF 
binding [99] and maintenance of centrosome duplication [263]. As such, it is hypothesised 
that the relocation of NPMc back to the nucleus could restore its nuclear functions, as well 
as limiting leukaemia-promoting cytoplasmic activity, leading to the suppression of the 
leukaemogenic effects of NPMc. 
Leptomycin B is a nanomolar inhibitor of the nuclear export transporter protein Crm1 that 
has shown promising results in the laboratory in activating tumour suppressor genes 
including p53 and its downstream target genes. However, clinical use of leptomycin B 
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demonstrated that it exhibited significant, unacceptable toxicity, leading to its rejection as 
a viable chemotherapeutic agent. Nonetheless, new compounds were synthesised based on 
the mode of action of leptomycin B, and these new drugs created by Karyopharm 
Therapeutics were optimised to exhibit the same inhibitory effect on Crm1 as leptomycin 
B while reducing the toxicity towards organisms treated with them. 
Like leptomycin B, the Karyopharm compounds (KPTs) were able to cause NPMc to 
relocalise back to the nucleus in AML3 cells. More importantly, while the use of KPT-185 
alone did not bring about a significant induction of cell death, it synergised with nutlin-3, 
an Mdm2 antagonist shown to activate p53 by blocking its inhibition and ubiquitination by 
its E3 ligase Mdm2. This synergism between KPT-185 and nutlin-3 caused the nutlin-
resistant AML3 cells to undergo significant amounts of cell death. This suggests that the 
nuclear export inhibitors are viable for use in the treatment of nutlin-resistant AML. 
Interestingly, the effect of KPT-185 in AraC-induced cell death was not significant, and 
KPT-185 instead rescued AML2 cells from AraC-induced apoptosis. This observation 
indicates that while KPT-185 may be useful in the combinatory treatment with nutlin-3, 
the use of KPT-185 together with traditional chemotherapeutic agents should be 
investigated with greater scrutiny. Regardless, the observations in Chapter 4 indicate that 
nuclear export inhibitors are a viable option in the treatment of NPMc positive AML. 
6.1.3 Role of Mdm4 in the activation of p53 for AML treatment 
While testing for the ability for KPTs to induce p53 in AML, it was observed that there 
was a constitutively high basal level of p53 in AML2 cells even without cytotoxic treatment. 
The p53 levels in the AML cell lines were assessed by Western blotting as well as flow 
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cytometry, and both methods revealed a greatly increased amount of p53 in untreated 
AML2 cells. High levels of p53 are commonly indicative of the presence of p53 mutations, 
or abnormalities in its negative regulators Mdm2 and Mdm4. However, p53 in AML2 was 
verified to be wild type, as are Mdm2 and Mdm4. Elevated levels of wild type p53 are 
normally associated with cells undergoing cell cycle inhibition or cell death, of which 
neither were observed in AML2 cells. Therefore, we hypothesised that the p53 in AML2 
cells were inhibited in a manner to prevent premature activation. 
Indeed, when comparing the levels of p53, and its negative regulators Mdm2 and Mdm4, 
it was noted that Mdm4 levels in AML2 were significantly higher compared to AML3. In 
addition to its role in the polyubiquitination of p53, Mdm4 was shown to be able to bind to 
p53 to inhibit its transactivational activity, as well as sequester p53 to the cytoplasm. In 
this study, we demonstrated that Mdm4 in AML2 was endogenously upregulated and 
exhibited a longer half-life compared to that in AML3 cells. This was also associated with 
a high level of p53 that demonstrated greater stability. Moreover, p53 in AML2 was found 
to be complexed to Mdm4, and as reported, this interaction occurred predominantly in the 
cytoplasm. In all, the results indicated that the high levels of p53 in AML2 was kept 
inactive and sequestered in the cytoplasm by Mdm4, and that high levels of Mdm4 
prevented the degradation of p53, extending its half-life beyond that of p53 in AML3 cells. 
However, the results do not conclusively implicate that apoptosis in response to Mdm4 
knockdown is p53-dependent. Therefore, it is to be determined if the apoptosis observed is 




Amplification of Mdm2 and Mdm4 have been observed in several types of cancers with 
wild type p53 and their increased levels are critical in inhibiting the activity of p53, 
primarily by preventing its accumulation. In this study, increased levels of Mdm4 was 
instead associated with p53 accumulation. While the reduction of Mdm4 by RNAi did not 
reduce the levels of p53 in AML2 cells, it resulted in PARP cleavage and cell death in 
AML2, but not in AML3. It could be likely that by uncoupling of Mdm4 from p53, the 
sudden release of large amounts of p53 led to an irreversible induction of apoptosis. In 
conclusion, this observation highlights the importance of targeting Mdm4 in treating 
certain types of AML and points to the potential use of Mdm4 inhibitors in anti-leukaemia 
therapy. 
6.2 Specificity and selectivity at targeting leukaemic cells 
The main aim in targeted therapy of cancer is to specifically treat cancer cells while limiting 
toxicity to normal cells. These new methodologies must at least have similar efficacies to 
conventional treatment, if not better, and must have lowered incidence and severity of side 
effects. Therefore, it is crucial that targeted therapies have selective activity towards cancer 
cells but not normal cells.  
Inhibitors of autophagy have been used in the treatment of diseases for the past 60 years. 
In fact, the most widely used inhibitor is chloroquine, though its main use is in the 
prophylactic treatment of malaria. Because of its long history and excellent safety track 
records, several clinical trials involving the use of chloroquine in anti-tumour therapy are 
already underway [319]. However, as chloroquine blocks the acidification of lysosome and 
inhibit the final stages of autophagy, better candidates for anti-tumour therapies that 
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specifically target the upstream signalling and initiation of autophagy should be considered. 
Recently, a small molecule inhibitor of autophagy spautin-1 has been reported to 
specifically prevent autophagy signalling by inhibiting ubiquitin-specific peptidases that 
target Beclin1 for degradation [320]. In vitro studies demonstrated that some cancer cell 
lines are sensitive to spautin-1 treatment under starvation conditions, making spautin-1 a 
possible drug for developing a new class of autophagy inhibitors suitable for therapeutic 
uses. However, as no in vivo studies involving spautin-1 have been reported thus far, it 
remains to be seen whether the inhibitor of autophagy has any detrimental effect on 
organisms. Regardless, if the hypothesis still stands, NPMc-expressing AML cells that 
depend on autophagy in preventing cell death would respond readily to a combinatory 
treatment involving autophagy inhibition and cytotoxic induction. 
Selective inhibitors of nuclear export designed by Karyopharm Therapeutics, however, 
have recently been reported to demonstrate excellent selectivity in targeting chronic 
lymphocytic leukaemic, but not normal cells [321]. Though the use of KPTs alone in this 
study did not induce similar levels of cell death on AML cells, it is likely that these 
inhibitors show similar selectivity on AML. Currently, these nuclear export inhibitors are 
undergoing phase I clinical trials, and their application in AML therapy may soon follow. 
The selectivity of nutlin-3 has been established in several reports. Vassilev et al. [271] 
demonstrated that nutlins were well tolerated in mouse xenograft models without genotoxic 
effects. In a study by Kojima et al. [274], nutlin-3 was reported not to exhibit cytotoxicity 
to normal mesenchymal stromal cells despite inducing apoptosis in AML cells in co-culture. 
Nutlin-3 was also found to be non-cytotoxic towards a variety of other blood cells as well 
[275, 276]. In addition, Shangary et al. [322] observed that nultin-3 also displayed no 
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cytotoxicity towards mammary and renal epithelial cells, and lung, colon and foreskin 
fibroblasts. In fact, nutlin-3 and its derivatives are currently in use in ongoing clinical trials 
and have shown positive results [278]. 
Unlike the case for Mdm2 antagonists, the recognition of the importance of Mdm4 in 
mediating p53 activity did not occur until recent years. As such, while the knockdown of 
Mdm4 and the use of peptide or small molecule inhibitors of Mdm4 have been reported to 
successfully induce apoptosis in several cancer cell types, no in vivo model testing the 
effect of Mdm4 inhibition have been reported thus far. Nonetheless, inhibition of Mdm4 
remains a potential avenue in treating AML with wild type p53, especially in cases where 
Mdm4 is overexpressed. 
6.3 Criticisms and future work 
While the results in this study points to the potential of several avenues by which targeted 
therapy of a large subset of AML can be achieved, there are several points that can be made 
to strengthen the conclusions. 
6.3.1 Establishment of autophagy inhibition as a viable anti-AML treatment 
While the observation of autophagic vesicles in adherent cells is relatively simple, it is not 
so in leukaemic cells that have little cytoplasm that surrounds a large nucleus. Shvets et al. 
[323] reported a methods utilising flow cytometry to analyse autophagy in an automated, 
objective manner, minimising the use of complicated image analysis and algorithms. 
Furthermore, this method would skirt around the problem of imaging leukaemic cells to 
obtain quantitative information. 
119 
 
Autophagy inhibitors like 3MA and wortmannin act by inhibiting phosphotidylinositol 3- 
kinases (PI3K), and the problem is that there are several classes of PI3K. This is 
confounded by the fact that class I PI3K inhibit autophagy while class III PI3K promote 
autophagy [324]. While these inhibitors have been established to prevent autophagy, their 
activities may be cell type dependent. As such, it would be prudent to look into ways to 
specifically target autophagy, either by the use of inhibitors that act through other pathways, 
such as the small molecule inhibitor spautin-1, or by the RNAi of autophagy related genes 
such as ATG5 or ATG12. 
It may be premature to conclude that NPM is not involved in the regulation of the 
Beclin1/PI3K III autophagy initiating complex. Given that the complex is made up of 
several large proteins, there is a possibility that the antibodies used in the study bind to 
epitopes that are concealed by the interactions with partner proteins. Therefore, the use of 
antibodies that recognise different epitopes might yield different results, possibly allowing 
the detection of complex formation and the competitive effect of NPM on Beclin-1/Bcl-2 
interaction. 
In order to conclusively establish autophagy inhibition as a viable anti-AML treatment, in 
vivo studies are required. Xenograft mouse studies would be useful in investigating the 
effects of autophagy inhibition on AML, especially when the bone marrow 
microenvironment plays a role in determining resistance towards chemotherapeutic agents.  
6.3.2 Nuclear export inhibition in AML treatment 
Other than NPMc, there are a variety of proteins that are central in mediating cell death, 
and a study of several of these proteins would yield detailed information on the mechanism 
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by which nuclear export inhibition leads to sensitisation of AML cells towards cytotoxic 
drug treatment. Also, the anomaly where KPT-185 rescued AML2 cells from AraC-
induced cell death should be investigated, especially when there exists the likelihood of 
treating an AML patient with leukaemic cells similar to AML2, and that despite being in 
use for the past four decades, AraC still remains an important form of chemotherapy against 
AML. 
The use of nuclear export inhibitors do not allow a distinction between the effects of the 
presence of cytosolic NPM and the absence of nuclear NPM on the cancer phenotype of 
AML cells. To determine which mechanism leads to the resistance of NPMc+ AML cells 
towards cell death, cytoplasmic NPM can be specifically knocked down with siRNA 
specific only to the mutant sequence. Alternatively, wild type NPM can be overexpressed 
to restore nuclear NPM, and its effects on cell death resistance can be assayed. 
In addition, as with autophagy inhibitors, in vivo studies on xenograft mice would yield 
greater information on the specificity and efficacy of combinatory treatment with selective 
inhibitors of nuclear export. 
6.3.3 p53 and Mdm4 levels in AML2 cells 
There have been many studies on the effects of Mdm4 on p53 activity, but the observations 
made in those studies involve the induced overexpression of Mdm4, which can lead to 
artificial results and conclusions. In this study, an AML cell line was found to 
endogenously overexpress Mdm4, and the advantage of this system is that it would be more 




The preferential interaction of p53 with Mdm4 in AML2 cells was established with an 
ELISA. While useful, the assay did not offer a qualitative insight on whether p53 interacted 
with Mdm2 and Mdm4 alone, or in homo- and heterodimers of Mdm2 and Mdm4. In order 
to determine the stoichiometry of p53, Mdm2 and Mdm4 required to cause p53 inactivation 
or p53 mono- or polyubiquitination, a more detailed, in vitro assay using recombinant 
proteins would be required. Furthermore, as these proteins undergo extensive post-
translational modifications, it would be insightful to study certain types of modifications 
and their roles in affecting the stoichiometry and fate of p53. For instance, the ELISA can 
be coupled with a mass spectrometric analysis of a co-immunoprecipitation of p53, Mdm2 
and Mdm4 to determine which modified species are involved in p53 preferentially binding 
to Mdm4 instead of Mdm2.  
The proximity ligation assay is a powerful tool to visualise single interaction events in cells. 
Besides looking at the interaction between p53 and Mdm4, the interactions between p53 
and Mdm2, and Mdm2 and Mdm4 can be similarly studied, and would give inferences 
about p53 ubiquitination and Mdm2/Mdm4 degradation. Unfortunately, the limitation of 
PLISA is that it is only suitable for binary interactions. Protein complexes made up of more 
than one protein cannot be visualised effectively. As such, the interaction between p53, 
Mdm2 and Mdm4 can at most be visualised with PLISA one pair at a time, and this would 
not provide sufficient information on the stoichiometry that affects the stability and activity 
of p53. 
While the knockdown of Mdm4 in AML2 cells did not result in the upregulation of Mdm2 
and p21 protein levels, it would be worthwhile to determine whether these genes are 
activated and transcribed. The absence or presence of transcription of these p53 dependent 
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genes would be useful in determining the role of p53 in the apoptosis of AML2 cells 
induced by Mdm4 knockdown. Also, Mdm2 and p21 may not accurately represent the 
transcriptional activity of p53. Since there are many p53 target genes that are directly 
involved in mediating cell death, a microarray analysis of all known p53 target genes can 
be performed to determine if there is activation of pro-apoptotic genes and/or repression of 
anti-apoptotic genes in response to Mdm4 knockdown.  
A concurrent knockdown of p53 and Mdm4 would also provide more conclusive evidence 
on the involvement of p53 in mediating cell death in AML2 cells. In addition, knockdown 
of Mdm4 in AML2 cells would be ideal to determine if the ensuing cell death is dependent 
on the transcriptional-independent roles of p53. 
Apoptosis in response to Mdm4 knockdown may be due to an unknown tumour suppressor 
that may be sequestered and inactivated by the high levels of Mdm4. A co-
immunoprecipitation coupled with mass spectrometry can be performed to isolate and 
identify the protein, or to rule out the possibility of its existence.  
When immunoblotting for Mdm4, another protein that is more electrophoretically mobile 
than Mdm4 at 51kDa was detected. As the level of this protein was also diminished in the 
RNAi of Mdm4 using a pool of siRNA against the Mdm4 ORF, it is likely that this smaller 
protein is a modified form or isoform of Mdm4. Moreover, this protein is predominantly 
nuclear, compared to the cytoplasmic localisation of full length Mdm4. Like Mdm2, there 
are several Mdm4 isoforms identified, though some of them are found in normal tissues, 
many of them are mostly identified only in tumour samples [325]. Unfortunately, none of 
the identified isoforms correspond to the smaller protein. Given that the anti-Mdm4 
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antibody used recognises Mdm4 between residues 125 and 175, the smaller protein could 
either be the result of a truncation at the N-terminus, which contains the p53 interaction 
domain, or the C-terminus, which contains the Mdm2-interacting RING domain. In either 
case, the smaller protein can potentially have significant impact on the p53/Mdm2/Mdm4 
complex formation. An immunoprecipitation with the anti-Mdm4 antibody can be used to 
isolate the protein in question and mass spectrometry can be performed to determine the 
identity and sequence of the potential new isoform.  
As with autophagy and nuclear export inhibitors, the effect of Mdm4 inhibition on AML 
treatment must be verified in an in vivo system. Though it may not be viable to use siRNA 
against Mdm4 for the treatment of whole organisms, several groups have designed peptide 
or small molecule inhibitors of Mdm4. For instance, SAH-p53-8, a cell-penetrating helical 
peptide that binds to Mdm4 at the p53-binding groove, may be used to disrupt the p53-
Mdm4 interaction [312]. Another example are the phage derived stapled peptides sMTide-
02/02A, which show great specificity and potency against both Mdm2 and Mdm4 [326]. 
These inhibitors can be used in AML xenograft mouse models to determine the feasibility 
of the inhibition of Mdm4 in the treatment of AML. 
6.4 Final remarks 
The results of this study highlight the use of novel ways for the treatment of AML by 
leveraging on the mechanisms by which leukaemic cells escape cell death. In particular, 
this study investigated the roles which cytoprotective autophagy play in conferring 
resistance towards cell death in NPMc+ AML cells, as well as how inhibiting autophagy 
in these AML cells result in an abolishment of such resistance. Also, this study looked into 
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the use of nuclear export inhibitors to relocalise the mutant NPMc from the cytoplasm back 
into the nucleus, and establishing it as a potential novel method to treat NPMc+ AML. 
Lastly, this study examined the accumulation of wild type p53 in AML2 cells and 
highlights how a high endogenous level of Mdm4 inhibits and sequesters the p53 in the 
cytoplasm, thereby preventing cell death. The observations here also indicate that the 
targeting of Mdm4 may be crucial in the treatment of AML where Mdm4 is amplified. In 
conclusion, this study has resulted in new insights into the disease mechanisms of the two 
common occurrences of AML and has proposed new, alternate strategies to treat these 
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